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Abstract 
Stroke is the most common cause of death worldwide. It is associated with high fibrinogen levels in 
plasma. Fibrinogen promotes clot formation, which in some situations can promote venous 
thromboembolism. Amyotrophic Lateral Sclerosis (ALS) is a devastating and fatal neurodegenerative 
disease, leading to severe respiratory insufficiency and hypoxia. 
The main goals of this study were: (i) to study the influence of fibrinogen on erythrocytes adhesion in 
stroke patients; and, (ii) to evaluate morphological and elasticity changes on erythrocytes from ALS 
patients. 
Human blood samples from stroke and ALS patients were analysed and compared with healthy donors 
(control).  
Samples were analysed by Atomic Force Microscopy (AFM) and through haemorheological 
parameters. AFM was used to measure fibrinogen-erythrocyte and erythrocyte-erythrocyte 
interactions, as well as erythrocyte stiffness and morphology. Erythrocyte membrane fluidity and zeta-
potential were also assessed on ALS. 
Erythrocytes from stroke patients are less deformable and have more propensity to aggregate. 
Fibrinogen-erythrocytes interactions on stroke are stronger than for the control group. They also have 
an increased concentration of ´ fibrinogen variant. These changes could be associated with high risk 
of cardiovascular events and a worst prognostic of the disease. 
Erythrocytes from ALS patients are more capable to deform and present morphological changes. 
Changes in erythrocytes physical-chemical and electrical properties and on their membrane 
organization were also observed.  
These findings could help to consider the fibrinogen-erythrocyte binding as a new cardiovascular risk 
factor for stroke disease. Understanding the role of fibrinogen on erythrocyte aggregation may be 
relevant for potential future drug interventions to reduce aggregation and enhance microcirculatory 
flow conditions. Fibrinogen in ALS disease could promote venous thrombotic events. In the future, 
finding a molecular biomarker of early respiratory dysfunction in ALS disease that could comprise 
prognostic value will be essential.   
 
 
 
 
 
Keywords: Stroke; Amyotrophic Lateral Sclerosis (ALS); Atomic Force Microscopy (AFM); 
Erythrocyte; Fibrinogen.  
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Resumo 
O acidente vascular cerebral (AVC) é a maior causa de morte mundial. A ele estão associados 
elevados níveis de fibrinogénio plasmáticos. O fibrinogénio promove o processo de coagulação 
sanguínea, podendo nalgumas situações conduzir a tromboembolismo venoso. A Esclerose Lateral 
Amiotrófica (ELA) é uma doença neurodegenerativa fatal, podendo conduzir a insuficiência 
respiratória e hipóxia.  
Os principais objetivos deste estudo foram: (i) estudar a influência do fibrinogénio na adesão 
eritrocitária em doentes com AVC; (ii) avaliar alterações morfológicas e de elasticidade nos eritrócitos 
de doentes com ELA.  
Amostras de sangue humano de doentes com AVC e ELA foram comparadas com amostras de 
dadores saudáveis (controlo). Estas foram analisadas por microscopia de força atómica (AFM) e por 
parâmetros hemorreológicos. Por AFM estudaram-se interações fibrinogénio-eritrócito e adesão 
eritrócito-eritrócito, assim como a elasticidade e morfologia eritrocitárias. A fluidez da membrana e o 
seu potencial zeta foram também avaliados na ELA.  
Os eritrócitos de doentes com AVC são menos deformáveis e têm mais propensão para agregar. As 
interações fibrinogénio-eritrócito são mais fortes que no grupo controlo. Estes doentes têm também 
um aumento da concentração de fibrinogénio ´. Estas alterações poderão estar associadas ao elevado 
risco de eventos cardiovasculares e ao mau prognóstico da doença.  
Os eritrócitos de ELA são mais deformáveis e têm alterações morfológicas. Alterações físico-químicas 
e das propriedades elétricas dos eritrócitos, bem como da sua membrana foram também observadas.  
Estes resultados permitem identificar a interação fibrinogénio-eritrócito como novo fator de risco 
cardiovascular em AVC. O papel do fibrinogénio na agregação eritrocitária poderá ser relevante na 
futura utilização de fármacos que reduzam a agregação e melhorem a microcirculação. Em ELA, o 
fibrinogénio poderá promover tromboembolismo venoso. O desenvolvimento de um biomarcador 
molecular precoce de disfunção respiratória na ELA com valor no prognóstico da doença é assim 
essencial.  
 
 
 
 
 
Palavras-Chave: Acidente Vascular Cerebral (AVC); Esclerose Lateral Amiotrófica (ELA); 
Microscópio de Força Atómica; Eritrócito; Fibrinogénio. 
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I) General Introduction 
1) Stroke 
The cardiovascular diseases (CVD) are the most common cause of death in the world. In 2012, it was 
estimated that 17.5 million people died from CVD, from which an estimated 7.4 million deaths were 
due to coronary heart disease and 6.7 million were due to stroke (World Health Organization, 2016). 
Coronary heart disease (CHD) and stroke are prevalent in the world, and 35%–65% of all deaths can 
be traced to CVD (vd. Figure I.1). Typically, the rate of CHD deaths exceeds that of stroke by a ratio 
from 2:1 to 3:1. During this period, average life expectancy surpasses 50 years. Roughly, 35% of the 
world's population falls into this category (Longo et al., 2012). 
 
Figure I.1 - Cardiovascular diseases are the main cause of death in the world (31%). The ischaemic heart diseases and the 
cerebrovascular diseases promote the major part of the CVD deaths. Adapted from (Cannon, 2013). 
In Portugal, cardiovascular diseases are also the leading cause of death. In 2012, 32,859 people died 
from CVD; from those, 14,393 were male and 18,466 female (Sociedade Portuguesa de Cardiologia, 
2015). 
By 2030, when the world population is expected to reach 8.2 billion, 33% of all deaths are expected to 
be of CVD (v.d. Figure I.2). Also, it is expected that 14.9% of deaths which will occur in men and 
13.1% of deaths occur in women will be due to CHD. Stroke is being responsible for 10.4% of all 
male deaths and 11.8% of all female deaths (Longo et al., 2012). 
 
Figure I.2 - By 2030, it is expected that cancer, ischaemic heart disease and stroke will be responsible for an increase of 
deaths in the world. Adapted from (Cannon, 2013). 
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The development of a clot in the coronary or cerebral circulation is the cause of an acute myocardial 
infarction or ischaemic stroke, respectively (Jackson, 2011). Acute myocardial infarction (AMI) and 
stroke are the most frequent cardiovascular diseases. In real life, stroke does not always have an 
announcement. It can be silence and quick. Acute events are mainly caused by a blockage of blood 
circulation that prevents blood from flowing to the heart or brain. This process is mainly due to 
atherosclerosis. Atherosclerosis happens when coronary arteries, which supply the heart with blood, 
slowly become thicker and harder from a build-up of fat, cholesterol and other substances, forming an 
atherosclerotic plaque. If an atherosclerotic plaque ruptures, a blood clot can be formed, and it can 
travel through the bloodstream, where it can lodge on the artery of the brain, blocking the flow of the 
oxygen-rich blood. When the blood flow is blocked, the supply of oxygen does not reach part of brain 
cells and these are damaged or die (Sociedade Portuguesa de Cardiologia, 2015). 
Stroke can also be caused by bleeding from a blood vessel in the brain or from blood clots (World 
Health Organization, 2016). As, it can be seen in Figure I.3, stroke is caused by the disruption of the 
blood supply to the brain. This may result from either blockage (ischaemic stroke) or rupture of a 
blood vessel (haemorrhagic stroke) (World Health Organization, 2002). 
 
Figure I.3 - Process of a blood clot blocking the blood flow, in the brain artery. When this process occurs, blood flow is 
blocked, promoting a stroke. 
Figure from (http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0063013/bin/stroke_ischemic.jpg). 
 
1.1) Cardiovascular Risk Factors 
The evaluation of novel risk factors can help to identify individuals at higher cardiovascular risk. The 
prevention of CVD focuses on identifying and managing risk factors, both on the entire population and 
at individual levels through primordial, primary and secondary prevention. Other causes of CVD are 
usually the presence of a combination of risk factors, such as unhealthy diet, obesity, physical 
inactivity, tobacco and alcohol habits. These CV risk factors may lead to other clinical complications, 
such as hypertension, diabetes mellitus and hyperlipidaemia (Sociedade Portuguesa de Cardiologia, 
2015). At the individual level, for the prevention of the first cases of cardiovascular disease, individual 
-3- 
health-care intervention needs to be targeted to those at high cardiovascular risk and high risk factor 
levels. For the secondary prevention of cardiovascular diseases, medication becomes necessary. 
Studies concerning high levels of fibrinogen in blood plasma have associated it with a wide variety of 
thrombotic diseases, such as stroke. Fibrinogen has been identified as a major independent risk factor 
for cardiovascular disease (De Oliveira et al., 2012). High fibrinogen levels promote fibrin formation 
and it is a major contributor to plasma viscosity (Stec et al., 2000). Increased levels of plasma 
fibrinogen result in changes in blood rheological properties, and these alterations exacerbate the 
complications in peripheral blood circulation during cardiovascular pathologies. Erythrocyte 
aggregation is also important, together with fibrinogen and lipids concentration on plasma to 
understand the risk of primary and secondary cardiovascular events. The interaction between 
fibrinogen and erythrocytes could be an important indicator of a high cardiovascular risk. 
2) Erythrocytes 
Erythrocytes, or red blood cells (RBC), are the most abundant cell type in blood. They are flexible, 
biconcave, enucleate cells derived from bone marrow. Erythrocytes circulate at 4.2-6.1×10
9
 cells/mL 
in humans, having men slightly higher values than women. Erythrocytes are highly specialized cells 
that carry oxygen from the lungs to the body cells and tissues to the lungs via its haemoglobin-rich 
cytoplasm (Baskurt & Meiselman, 2003; Dzierzak & Philipsen, 2013; Aleman et al., 2014). Human 
erythrocytes have an in vivo life span of approximately 120 days and they are selectively removed 
from circulation via phagocytosis. During its life span, the erythrocyte undergoes progressive physical 
and chemical changes, such as the decrease on cell volume with cell aging. This is presumably due to 
the loss of potassium and the loss of membrane patches by microvesiculation, resulting in an increase 
on cell density (Carvalho et al., 2011). 
Usually, mature erythrocytes are biconcave disks, with about 8 μm in diameter, however erythrocytes 
can measure between 6.6 to 7.5 μm. Healthy erythrocytes have a thickness of 2 μm, surface area of 
135 µm
2
 and volume of 90 fL. They are composed by haemoglobin (32%), water (65%), and 
membrane tissue (3%) (Yurkin et al., 2005). The erythrocyte membrane is composed of a lipid bilayer, 
transmembrane proteins, and a filamentous meshwork of proteins that forms a membrane skeleton 
along the entire cytoplasmic surface of the membrane, as it can be seen in Figure I.4. The erythrocyte 
membrane skeleton has spectrin as its most abundant protein, which forms long, flexible heterodimers 
through the lateral association between chains. These chains can form heterotetramers that bind a 
junctional complex (JC) composed of F-actin, protein 4.1 and the actin-binding proteins dematin, 
adducin, trompomyosin and tropomodulin. Spectrin and actin are two main structural proteins and, 
together, form a submembranous cytoskeletal meshwork. It is responsible for the viscoelastic 
properties of the erythrocyte membrane. Band 3, or the anion channel, other compound of the 
erythrocyte membrane, is a major transmembranous protein involved in the transport of water and 
-4- 
anions. It is a carrier of the blood-group-I antigen. Glycophorin A, a sialic acid-rich glycoprotein, is 
the major contact or receptor membrane polypeptide that also spans the lipid bilayer. This network is 
tethered to the cell membrane at two sites: one mediated by ankyrin, that couples spectrin to band 3, 
and the other mediated by protein 4.1, that couples the junctional complex to glycophorin C/D (Kim et 
al., 2015). 
 
Figure I.4 - The erythrocyte membrane is composed by a lipid bilayer, transmembrane proteins and a filamentous meshwork 
of proteins that forms a membrane skeleton along the entire cytoplasmic surface of the membrane. Membrane proteins are 
also asymmetrically oriented within the lipid bilayer and can be divided into three functional sets: structural, catalytic and 
receptor proteins. Figure from (Kim et al., 2015). 
 
3) Fibrinogen 
3.1) Total Plasma Fibrinogen 
Fibrinogen is a natural occurring protein in human blood. It is a large, complex and multifunctional 
plasma glycoprotein synthesised by hepatocytes (Mannila et al., 2007) in the liver that is essential for 
haemostasis (stopping blood loss from damaged tissues), wound healing, fibrinolysis, inflammation, 
angiogenesis, cellular and matrix interactions, and neoplasia (Averett & Schoenfisch, 2010; De 
Oliveira et al., 2012). Normally, fibrinogen in circulation has concentrations ranging from 2 to 4 
mg/mL (6-12 µM) (De Oliveira et al., 2012; Ariëns, 2013; Aleman et al., 2014), but people usually 
carry about 2.5 mg/mL of blood (Xu & Siedlecki, 2009). Sometimes, fibrinogen can circulate in 
excess, up to 7 mg/mL during acute inflammation (Wolberg, 2016). Fibrinogen is the third most 
abundant plasma protein and plays a prominent role on the development of surface-induced 
thrombosis due to its multi-functional role in serving as a ligand for platelet adhesion, linking platelets 
together into aggregates and stabilizing thrombi by forming a fibrin polymer (Xu & Siedlecki, 2009; 
Ariëns, 2013). Elevated fibrinogen levels are associated with increased risk of cardiovascular disease, 
primarily linked to myocardial infarction and stroke (Lovely et al., 2010; Kotzé et al., 2014; 
Domingues et al., 2016; Wolberg, 2016). 
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Fibrinogen is a dimeric 340 kDa plasma protein, composed by three pairs of polypeptides chains with 
bilateral symmetry (Aα2, Bβ2 and γ2) and 29 disulphide bonds (Mannila et al., 2007; Ariëns, 2013). 
Fibrinogen has an isoelectric point of about 5.5 at physiological conditions (vd. Figure I.5). 
 
Figure I.5 - Fibrinogen molecule. The polypeptides chain pairs are formed by Aα (blue), Bβ (red) and γ (green). They are 
oriented so that all six N-terminal ends meet to form the central E domain. Two regions of coiled-coil α helices stretch out on 
either side of the E domain. Each coiled-coil region ends in a globular D domain, containing the C-terminal ends of Bβ and γ 
chains, as well as part of Aα chain. The C-terminal end of the Aα chains protrudes from each D domain as a long strand 
(Mannila et al., 2007; Averett & Schoenfisch, 2010). The β- and γ-nodules are homologous and each of them contains three 
distinct globular domains. Adapted from (Zhmurov et al., 2011). 
 
Fibrinogen is involved in the coagulation cascade that leads to blood clotting, and it has a rapid 
response to tissue damage. Blood coagulation is a complex process that involves many collective 
players and factors. The physiological process of blood clotting and the subsequent dissolution of the 
clot, after repair of the injured tissue, are essential components of blood haemostasis (Wagner et al., 
2013). The coagulation cascade has been divided in two pathways: the intrinsic and the extrinsic 
pathways, this last one also named tissue factor pathway (Kilinç et al., 2011). After the damage of a 
vessel wall, there is the exposure of tissue factor (TF) to the bloodstream, initiating a fast cascade 
system (vd. Figure I.6). 
 
Figure I.6 - Blood coagulation cascade.  
(Adapted from http://www.ebi.ac.uk/interpro/potm/2006_11/Page1.htm). 
The coagulation cascade begins with a tissue factor, known by thromboplastin, which is a 47 kDa 
protein expressed in both vascular and nonvascular cells. The tissue factor in circulation activates 
many other factors initiating the cascade. When the complex is in the presence of factor Va and 
calcium, factor Xa catalyses the conversion of prothrombin (FII) to thrombin (FIIa). Thrombin 
converts fibrinogen to fibrin, thereby leading to fibrin deposition, platelet activation and formation of a 
thrombus (Zhmurov et al., 2011). The activation of factor XIII to factor XIIIa can stabilise blood clots 
by cross-linking them (Steffel et al., 2006; Kilinç et al., 2011). 
Fibrin clots are proteinaceous gels that polymerize in the blood, as a consequence of the biochemical 
cascade presented above, at sites of vascular injury. Together with platelets, this meshwork stops the 
bleeding and supports active contraction during wound healing (Brown et al., 2009).  
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Fibrin is the main contributor for cardiovascular disorders. The plaque rupture can provide a scaffold 
for thrombi. Clots block blood vessels and cause tissue damage, leading to myocardial infarction, 
ischaemic stroke, or other cardiovascular diseases (Brown et al., 2009; Stefanelli & Barker, 2015). 
The process of conversion of fibrinogen to fibrin, namely the molecular mechanism that occurs when a 
blood clot is formed, is presented in Figures I.7 and I.8. Fibrinogen contains the central E region or 
domain, which includes the cleavage sites for thrombin. The E region is connected with two D 
domains that contain binding pockets important for polymerization. The elasticity of fibrinogen result 
by the connection of D and E regions through two coiled coil chains (Ariëns, 2013). Both these 
domains contain important binding sites for the conversion of fibrinogen to fibrin, fibrin assembly and 
crosslinking, and platelet aggregation. The calcium ions are important to help maintaining the 
structure of fibrinogen. The N-terminus of Aα and Bβ polypeptides are cleaved by thrombin in order 
to turn soluble fibrinogen into gel-forming fibrin. Once cleaved from fibrinogen, the N-terminal ends 
are known as fibrinopeptide A (from Aα polypeptide) and fibrinopeptide B (from Bβ polypeptide). It 
is known that fibrinogen is a component of the coagulation cascade as well as a determinant in plasma 
viscosity and erythrocyte aggregation (De Oliveira et al., 2012). 
 
Figure I.7 - Conversion of fibrinogen to fibrin. First, fibrinogen can be cleaved by serine protease thrombin to remove the 
fibrinopeptides A (blue chain) and B (pink chain), from the central N-terminal disulphide knot ends of Aα and Bβ. This can 
expose the terminal ends on the E domain, enabling the interaction with the holes (“a” and “b”) present on the D domains. 
Thereby, the fibrinogen monomers are transformed in fibrin. Adapted from (Stefanelli & Barker, 2015). 
 
The Aα protuberances can interact with each other and with the E domain of the fibrinogen molecule 
during fibrin clot crosslinking (Mannila et al., 2007; Averett & Schoenfisch, 2010). Fibrinopeptide A 
is cleaved at a faster rate than fibrinopeptide B. Fibrinopeptide A exposes a binding site (GPR) on the 
fibrin E region for a specific binding of one fibrin molecule with two other fibrin molecules (Ariëns, 
2013). 
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Figure I.8 - Fibrin protofibril formation process. Fibrin molecules can link together through the interaction of the E domain 
on one fibrin molecule to the D domains on other fibrin molecules, thereby polymerising to form staggered oligomers that 
build up into protofibrils. The knobs “A” (blue colour) are as prominent as knobs “B”(pink colour) for protofibril formation. 
The non-covalent knobs “A” are exposed more rapidly, but the knobs “B” are more important for the lateral aggregation of 
protofibrils. As the fibrin oligomers aggregate, these protofibrils continue to lengthen to make long fibres that can wind 
around one another to make multi-stranded, thick bundles, and which can branch into a 3-dimentional network of entangled 
fibres, the fibrin clot. When the transglutaminase factor XIII (FXIIIa) is activated and stabilised subsequently by crosslinking 
with adjacent D regions within a protofibril form DD-Dimers. This occurs between the C-terminal ends (Aα protuberances) 
of the Aα polypeptides, as well as (more slowly) at other sites, such as between the C-terminal ends of γ chains (green 
colour). Only Aα and γ chains become crosslinked by FXIIIa. When fibrin is cleaved by plasmin, the resulting products are 
DD(E) complex, DD-dimer and E-fragment. Adapted from (Stefanelli & Barker, 2015).  
 
When fibrinopeptide B is cleaved by thrombin, it exposes a second binding site (GHR) in the E region. 
Other specific binding pocket in the fibrin D region results from the release of the αC region, causing a 
tether along the fibrinogen E region, which becomes available for intermolecular interactions between 
fibrin molecules. These interactions contribute to lateral aggregation between protofibrils and fibrin 
fibres (Stefanelli & Barker, 2015).  
When a blood vessel is damaged, platelets prevent the occurrence of extensive bleeding, with the 
formation of a blood clot, kept together by a dense fibrin network (Carvalho et al., 2015).  
The fibrin network structure depends of fibrinogen and thrombin concentration. In the presence of 
high fibrinogen levels, the density of the fibrin network increases, as well as the clot stiffness, and the 
resistance of the clots to fibrinolysis (Aleman et al., 2014). Fibrinogen can also mediate platelet 
aggregation and adhesion. It has two recognition binding sites sequences for platelet receptor: RGD, 
on the Aα subunits, and a carboxyl-terminal peptide on the γ subunits. The fibrinogen-platelet binding, 
essential for coagulation, depends on the platelet membrane receptor glycoprotein αIIbβ3 (Carvalho et 
al., 2011). This is the major integrin on platelets. It is essential for platelets aggregation and is 
centrally involved in haemostasis and thrombosis (Ma et al., 2007). 
 
Figure I.9 - Fibrinogen molecule with different recognition binding sites for distinct integrin receptors (αIIbβ3 and αVβ3). 
Adapted from (Springer et al., 2008). 
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Increased fibrinogen concentration and erythrocyte aggregation are factors that significantly increase 
the risk of cardiovascular and cerebrovascular diseases. Fibrinogen binding to the αIIbβ3 receptor 
requires calcium to activate the integrin complex. The effect of the absence of calcium is more 
pronounced for the fibrinogen-platelet system than for erythrocytes. Thus, the erythrocyte receptor for 
fibrinogen, is not as calcium dependent and as influenced by the presence of the eptifibatide as the 
platelet receptor. Its inhibition by eptifibatide indicates that the receptor for fibrinogen on erythrocytes 
is not the glycoprotein αIIbβ3, but a related integrin (Carvalho et al., 2010). 
It is known that the arterial thrombi have high levels of platelets and venous thrombi are mostly 
constituted by erythrocytes and fibrin (Aleman et al., 2014). In blood clot formation, erythrocytes are 
the major component of the thrombus. Venous thromboembolism is the third most common 
cardiovascular illness, after acute coronary syndrome and stroke (Wagner et al., 2013). 
 
Figure I.10 - Clots on arterial thrombosis can be called white clots, because they are mainly constituted by platelets. 
Accordingly, clots on venous thrombosis can be called red clots, due to their content in erythrocytes and fibrin (Aleman et 
al., 2014). TM – thrombomodulin; EPCR – endothelial protein C receptor; II – prothrombin; IIa – thrombin; TF – tissue 
factor; Fgn – fibrinogen; RBC – red blood cells. 
(Figures from https://www.med.unc.edu/wolberglab/images/arterial%20thrombosis.jpg/@@images/83373353-123c-476d-
af5c-97773048fac3.jpeg and https://www.med.unc.edu/wolberglab/images/venous%20thrombosis.jpg/image_preview). 
 
3.2) γ’ Fibrinogen  
Fibrinogen in plasma is a heterogeneous mixture of isoforms with different relative proportions.  
Fibrinogen variants are the result of alternative splicing of the γ-chain. mRNA processing and post-
translational modifications give rise to several different fibrinogen isoforms with widely varying 
characteristics. The γ’ isoform arises from alternative mRNA processing, leading to the substitution of 
the last 4 amino acid residues of the carboxyl terminal, by another 20-amino acid residues sequence. 
This is originated by the introducing of 20 new residues at the γ-chain C terminus by the open reading 
frame from intron 9, replacing 4 residues encoded by exon 10 followed by a stop codon. Thus, the 
fibrinogen γ chain has 2 isoforms: the gamma A (γA or simply γ) isoform and the gamma-prime (γ’ or 
γB) isoform. Therefore, at the level of the γ-chain the fibrinogen molecule can be a homodimer 
(γA/γA) that constitutes approximately 84% of the total plasma fibrinogen concentration, an 
heterodimer (γA/γ’) that are present in approximately 15% or an homodimer (γ’/γ’) that constitutes the 
remaining 1% of fibrinogen concentration (Lovely et al., 2010; Ariëns, 2013; Domingues et al., 2016; 
Macrae et al., 2016). 
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Figure I.11 - Proposed model of the γ’-chain of the fibrinogen molecule. The 20 amino acid extension of the γ′-chain is 
located at the C-terminus, on the D region of the fibrinogen molecule (red region). The 20 amino acid may extend the 
fibrinogen molecule 30 to 40 Å. Figure from (Macrae et al., 2016). 
 
The γ’ fibrinogen has several biochemical and biophysical properties that distinguish it from the more 
common γA isoform. This fibrinogen variant, has been reported to have more affinity on the binding 
to thrombin (Ariëns, 2013). It has been associated with a non-uniform clot structure with prolonged 
clot lysis time (Kotzé et al., 2014) and with various biological functions which are disclosed upon 
fibrin clot formation. When the fibrin clots are formed in the presence of γ’-chain fibrinogen variant, 
they are most resistant to fibrinolysis (Mannila et al., 2007; Domingues et al., 2016). Furthermore, the 
γ’ chain contains a binding site for thrombin, and clots made from γ’ fibrinogen have been reported to 
have altered clot architecture. γ’ fibrinogen forms thinner but denser fibrin fibres. Possibly as a result 
of these properties, recent studies suggest that γ’ fibrinogen is a risk factor for cardiovascular disease. 
This fibrinogen variant has been associated with the extent and severity of coronary artery disease and 
an increase risk of arterial thrombosis, myocardial infarction and stroke (Mannila et al., 2007; 
Domingues et al., 2016; Macrae et al., 2016).  
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4) Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disorder, 
characterized by rapid and progressive degeneration of motor neurons in the spinal cord, brainstem 
and motor cortex (Pronto-Laborinho et al., 2014), which results in muscle atrophy, paralysis and death 
(D’Angelo et al., 2013). ALS patients die mainly from respiratory failure, related to weakness of 
diaphragm and other respiratory muscles (Pronto-Laborinho et al., 2014).  
The worldwide incidence of ALS is between 1.5 and 2.5 per 100,000 persons per year, with a 
male/female ratio of 3:2. Most patients have first symptoms between 55-65 years and the median 
survival expectancy of ALS patients is 3-5 years after symptom onset (Pronto-Laborinho et al., 2014; 
Kioumourtzoglou et al., 2015). 
Most ALS cases are sporadic (SALS) (90-95%); the remaining 5-10% of patients have a positive 
family history for ALS or frontotemporal dementia (FALS) (Pronto-Laborinho et al., 2014; 
Kioumourtzoglou et al., 2016). More than 16 dysfunctional genes have been described in FALS, and 
approximately 20% of FALS patients have a missense mutation in the gene encoding the enzyme 
Cu/Zn super oxide dismutase (SOD1) (Pronto-Laborinho et al., 2014). 
ALS can have spinal, bulbar, respiratory, axial or diffuse form. ALS cases increase with increasing 
age (Kioumourtzoglou et al., 2015).  
Riluzole is the only drug currently approved in ALS, acting by decreasing glutamate activity in the 
central nervous system, which increases life expectancy on about 3-6 months. The etiology of ALS 
pathogenesis is complex and not completely understood. The mechanisms of the disease comprises 
oxidative stress, excitotoxicity, protein aggregates, mitochondrial dysfunction, neuroinflammation, 
cytoskeletal derangements, deregulated growth factors, impaired axonal transport and apoptosis, 
abnormal calcium metabolism and activation of proteases and nucleases (Pronto-Laborinho et al., 
2014). 
Several clinical prognostic factors have been identified in ALS, such as age, site of onset, functional 
and respiratory status, cognitive function, non-invasive ventilation, some genetic mutations, and 
clinical phenotypes (Chiò et al., 2014; Kioumourtzoglou et al., 2015). 
Previously, the main causes of death in ALS patients were respiratory problems, including respiratory 
muscle paralysis and bronchopneumonia (Tanaka et al., 2013). Some patients with respiratory-
dependent ALS die of sudden cardiac arrest or anoxic encephalopathy following circulatory collapse, 
which may be associated with sympathetic hyperactivity (Tanaka et al., 2013). However, recent 
studies, related that exist an inverse association between cardiometabolic health and ALS disease 
(Kioumourtzoglou et al., 2015). 
Other studies have demonstrated a protective association between ALS incidence and cardiovascular 
risk factors such as obesity, higher cholesterol levels and hyperlipidaemia. Diabetes has been 
associated with high levels of uric acid that prolonged survival in ALS (Kioumourtzoglou et al., 2015, 
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2016). Various biomarkers have been proposed as potentially related to a better ALS outcome, 
including dyslipidaemia, elevated levels of uric acid and creatinine, and reduced granulocyte count 
(Chiò et al., 2014).  
Venous Thromboembolism (VTE), a cardiovascular risk, is also associated with ALS disease. 
Neurologic diseases that affect lower limb function are described as risk factors for venous 
thromboembolism. ALS has several risk factors for VTE, such as reduced mobility, increased age and 
progressive respiratory failure. Thus, VTE is common in ALS patients (Gladman et al., 2014). 
Therefore, VTE is considered as a complication of ALS, and it is highly correlated with leg functions 
(Berry & Korngut, 2014). 
On another study, performed by Namazi et al. (2014), one ALS patient was diagnosed with heart 
failure at the final stage of the disease. However, the association between ALS and cardiovascular 
disease is rare and underdiagnosed, because symptoms are masqueraded as a result of the patients’ 
disability. Cardiac denervation related to involvement of the sympathetic nervous system has been 
depicted in patients in the early stages of ALS. Other studies indicated some metabolic abnormalities 
in central nervous system and systemic circulation. The sympathetic hyperfunction and vagal 
hypofunction of the cardiovascular system have a subclinical role in ALS patients (Chida et al., 1989). 
 
 
Figure I.12 - Regions of the nervous system that can be affected in ALS disease. All the nervous system has interrelation and 
when the upper and lower motor neurons undergo degeneration, other components can also be affected (Purves et al., 2004). 
 
The motor neuron disease (MND) phenotype, that has been described to involve the sympathetic 
nervous system, can also be attributable to cardiac denervation in patients in the early stages of ALS. 
This result is related with the fact that the levels of norepinephrine and epinephrine are increased in 
ALS patients (Gdynia et al., 2006). Symptoms of an autonomic dysfunction are not a characteristic of 
ALS, although there are reports of cardiac arrhythmia (Sachs et al., 1985). 
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ALS can also lead to total paralysis and respiratory failure. Knowing that ALS patients frequently 
have respiratory failure, the diagnosis and treatment of cardiac arrhythmias revealed to be difficult. 
ALS affects the autonomic nervous system, which contributes for regulation of heart rate, blood 
pressure and others homeostatic functions. Thus, the cardiovascular autonomic dysfunction contributes 
to the morbidity of the disease. As previously described, sympathetic predominance with vagal 
withdrawal tends to occur in early stages of ALS disease. At these stages of the disease, the most 
common symptom is sinus tachycardia. Bradycardia results from sympathetic denervation. However, 
in advanced ALS, the spinal cord sympathetic ganglia (known as the intermediolateral nucleus) also 
undergo degeneration. In addition to late central sympathetic failure, there is also degeneration of 
peripherally mediated sympathetic nerves (Shemisa et al., 2014).  
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5) Atomic Force Microscopy 
Atomic Force Microscopy (AFM) is a technique that can be used for high-resolution real-time studies. 
It can both measures properties of molecules at the nanoscale and of dynamic changes in biological 
systems, such as cells, viruses and bacteria (Kim et al., 2003; Karagkiozaki et al., 2008; Variola, 
2015). AFM has contributed to nanomedicine with developments in nanodiagnostics and 
nanotherapeutics, contributing to the improvement of relevant healthcare processes (Carvalho et al., 
2015). 
Atomic force microscopy is a surface probe technique that uses a soft cantilever to image surfaces or 
to measure or apply forces while interacting with them (Cazaux et al., 2016). AFM key element is a 
small and flexible cantilever controlled in the z-direction by a piezoelectric crystal. The cantilever acts 
like a spring to measure the force between the tip and the sample’s surface (Averett & Schoenfisch, 
2010). The sharpened tip is brought into contact with the sample and moved across the surface. The 
instrument measures the deflection of the cantilever as it scans, and from this information about the tip 
movement a pseudo-three-dimensional image of the sample is built up (JPK Instruments AG, 2012; 
Variola, 2015) (vd. Figure I.13a). 
 
 
Figure I.13 - AFM principles. (a) The deflection of the cantilever is detected and processed as a function of the position on 
the (x, y) plane, in order to obtain topographical images (JPK Instruments AG, 2012). (b) AFM operation modes. The AFM 
can operate in a variety of modes, including contact, intermittent contact and force spectroscopy (Variola, 2015). (Adapted 
from http://static1.squarespace.com/static/51acda21e4b0be9ceadc57b3/t/538c8e2be4b01a84edc5f741/1401720367289/). 
 
The AFM can operate in different modes. The tip can be continuously contacting with the sample’s 
surface (contact mode), or the cantilever could be oscillating and the variations on its resonance 
frequency are used to generate images (intermittent contact or tapping mode). On this mode, the 
cantilever moves rapidly with a large oscillation between the repulsive and attractive forces (vd. 
Figure I.13b). An optical lever is created by a beam of light from a light-emitting diode reflected off of 
the cantilever onto a position-sensitive photodiode (Averett & Schoenfisch, 2010). Deflections of the 
cantilever cause changes in the position of the light spot, and may be translated into applied force 
using Hooke’s Law:  
 𝐹 = −𝐾∆𝑥 (1) 
Thus, a cantilever deflection vs. scanner displacement curve can be converted into a force-distance 
curve (Carvalho & Santos, 2012). This means that the force (F) needed to extend the cantilever spring 
a 
b 
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constant (K) depends in a linear way of the cantilever deflection (∆𝑥) that may extend it (JPK 
Instruments AG, 2012) (vd. Figure I.14). When the tip contacts the sample at a given point, the 
cantilever can move vertically and the deflection of the cantilever provided information on the 
mechanical properties of the sample’s surface or on the tip-sample interactions (force spectroscopy 
mode). 
 
Figure I.14 - Scheme of the AFM process and how to apply the Hooke’s Law to calibrate the cantilever (JPK Instruments 
AG, 2012). 
 
5.1) Atomic Force Microscopy Applications 
5.1.1) Cell Imaging  
Atomic force microscopy has been usually applied to characterize the nanometric features of the 
surfaces of samples and also to map the spatial distribution of their physicochemical properties. AFM 
has the capacity to visualize nanotopographical features and correlate them to surface charge density 
and electrical characteristics of the biomaterials. The contact and oscillation modes are most 
commonly used to image reconstituted membrane proteins and native membranes (Fotiadis, 2012). 
The AFM technique involves a small sensor scanning over the surface of the cell. AFM is typically an 
imaging technique in which the surface of a sample is scanned, line by line, by the movement of a thin 
tip mounted on a flexible cantilever. The tip-sample repulsion at the atomic level, transduced by the 
cantilever deflection and by an optical lever mechanism allows the association of a height value to 
each position on the x,y plane, enabling the reconstitution of a high-resolution pseudo-three-
dimensional image of the sample surface (Carvalho et al., 2015). AFM has the capacity of imaging, in 
air or in liquid, nonconductive and conductive surfaces beyond the light diffraction limit, reaching 
molecular and atomic resolution for some samples (Averett & Schoenfisch, 2010). Operating in 
contact mode, the force applied by the tip is constantly adjusted manually to image the sample in a 
non-perturbed state. In oscillation mode (intermittent contact), the cantilever is rapidly oscillated in the 
vertical direction while raster scanning the sample. Ideally, the AFM tip then only touches the sample 
on its downward movement and is not in constant contact with the sample as in contact mode. The 
‘tapping’ mode has the advantage that lateral forces and friction are virtually eliminated. Hence, the 
oscillation mode is particularly convenient for AFM imaging of soft and weakly adsorbed 
biomolecules. However, in spite of this considerable advantage, contact mode-AFM imaging still 
remains the operating mode of choice to achieve high resolution on native and reconstituted membrane 
protein surfaces (Fotiadis, 2012). AFM imaging of cells generates relevant structural information, 
allowing the identification of functional components on cells, and giving information about the 
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heterogeneity of the cell surface in terms of protein composition and distribution (Fotiadis, 2012; JPK 
Instruments AG, 2012; Variola, 2015). 
5.1.2) Atomic Force Microscopy-based Force Spectroscopy 
AFM-based Force Spectroscopy allows the measurement of inter and intramolecular interaction forces 
required to separate the tip from the sample, with piconewton (pN) resolution. Thus, the AFM can be 
used to quantify the interaction between the tip and a specific spot of the sample, taking advantage of 
the piconewton sensitivity of the method (Averett & Schoenfisch, 2010; Carvalho & Santos, 2012; 
Carvalho et al., 2015). 
The interaction force depends on the nature of the samples, the probe tips and the distance between 
them. It measures the interaction force between a sharp tip and a surface, or may vibrate as it moves 
along it. The design of a force-distance curve depends on these characteristics and of the composition 
of the medium. There are differences in curves obtained for measurements in air and in liquid medium. 
In force spectroscopy measurements, the cantilever moves in the vertical direction (z axis) toward the 
surface and then in the opposite direction. During this procedure, the cantilever deflection as a 
function of the vertical displacement of the piezoscanner can be recorded. The result is a cantilever 
deflection versus scanner displacement curve, which can be converted into a force-distance curve after 
applying the Hookes’s law of elasticity (Carvalho & Santos, 2012) (vd. Figure I.15). To obtain the 
quantitative parameters, the accurate calibration of the spring constant of the cantilevers is necessary 
(Averett & Schoenfisch, 2010). This technique can be used a highly sensitive nanotool for the 
diagnostic and unbiased functional evaluation of the severity of haematological diseases arising from 
genetic mutations. AFM-based force spectroscopy can be used to measure the binding force between 
fibrinogen and cell receptors and for the identification of the fibrinogen receptor on erythrocytes 
(Carvalho et al., 2010). Different types of forces can be studied using AFM-based force 
spectroscopy, both attractive and repulsive (Carvalho et al., 2013). 
 
 
Figure I.15 - AFM-based force spectroscopy. (a) Schematic representation of the force-distance curve obtained by AFM-
based force spectroscopy, showing a single adhesion event. The red line is the approach curve and the blue line is the 
retraction curve. (b) Diagram of the vertical tip movement during the approach and retraction curves of force spectroscopy 
measurements. The letters represent different moments during the approach and retraction curves. Adapted from (JPK 
Instruments AG, 2012; Carvalho et al., 2013). 
a 
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In Figure I.15, the cycle begins with the tip away from the cell surface (a) and the forces measured by 
the cantilever deflection can change as it is moved toward or away from the sample on its neutral 
position (0 pN). From this position, the tip starts moving down towards the surface, reaching the 
contact point (b). On the approach curve, the van der Waals interactions are the main type of force 
present on the approaching of two hard surfaces in the absence of long-range interactions. This force is 
characterized by a small deflection of the cantilever, at the approach curve, before the contact point. 
The jump to contact causes instability in the position of the cantilever because it occurs when the 
gradient of force between the tip and the sample exceeds the stiffness of the cantilever. If the approach 
curve has a smooth and exponentially increasing repulsive force, it is expectable that electrostatic or 
polymer-brush forces are present. Viscoelastic properties of some biological systems have been 
determined using AFM force curves. There is a waiting time before starting the retraction curve and 
another after reaching the defined applied force (c). Afterwards, tip and cantilever begin the upward 
movements away from the sample, in the opposite direction, reaching the contact/adhesion point (d). 
In the retraction curve, an adhesion force profile, the force depends on the type of the sample and 
appears as a deflection of the cantilever below the zero-deflection line (e). The central basis of 
adhesion forces is the development of a capillary bridge between the tip and the sample. This capillary 
force depends if the measurements are made in air or in liquid. In air, samples usually have several 
nanometers of water molecules adsorbed to their surface. In liquid conditions, the adhesion force not 
only depends of the interaction energies between tip and sample but also on the type of solution used. 
If no adhesion occurs between the molecules attached to the tip and the cell surface, the tip continues 
its upward movements, at 0 pN of force, and reaches back the neutral position at a defined z distance 
point (f). If a bond is formed between the tip and the sample, as the cantilever moves upward, it bends 
down to negative values in force. To quantitatively analyse force-distance curves, it is necessary to 
accurately calibrate the spring constant of the cantilevers. Cantilever stiffness depends on the shape 
and on the material properties of the cantilevers (JPK Instruments AG, 2012; Carvalho et al., 2013).  
5.1.2.1) Force Spectroscopy modes 
The AFM-based force spectroscopy can be used at diverse applications. The main application modes 
that were applied on this study were molecular interaction, adhesion and indentation. 
Molecular interactions studies 
Single-molecule force spectroscopy (SMFS) is an extremely powerful tool for detecting and localizing 
single molecular recognition events, and for exploring the energy landscape of molecular interactions. 
Different molecules, or their domains, can be attached to the tip, and each part of the molecule can 
break contact separately or altogether (Carvalho et al., 2013). After attaching a molecule to the tip 
and/or to the sample surface, the unfolding, stretching, or adhesion of single molecules can be studied. 
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The tips are commonly functionalized with one or a small amount of molecules. These molecules can 
recognize a specific target molecule on the sample surface. When analysing the stretching of 
biomolecules, and in order to measure specific and strong interactions between tip and sample, it is 
necessary to specifically attach to the tip the biomolecule under study. The attachment should be firm 
enough to avoid reallocations, but it should maintain some autonomy of the molecule to change its 
conformation during or before the interaction (Carvalho et al., 2013). The simplest method to attach 
molecules to the tip is via their non-specific adsorption. However, the covalent attachment methods 
usually yield better performances. With this process, parameters like stiffness, persistence length, and 
inter- or intramolecular transitions can be studied. Proteins can be unfolded in a controlled way, to 
explore the structure of the molecule (Carvalho et al., 2013). 
Indentation studies 
AFM-based detection of stiffness is highly dependent on the appropriate use of theoretical models. 
Cells elasticity can be measured by nanoindentation with the most common AFM cantilevers, via the 
Hertzian theory (Carvalho & Santos, 2012). This theory of elastic contact is the most widely used 
approach to estimate the elastic properties of cells from force indentation curves, using the depth of 
indentation to assess elasticity in terms of the Young’s elastic modulus. Specifically, this method 
allows characterizing the elasticity of biological structures, comparing different types of cells or even 
organelles. Experimental conditions concerns the indenters’ shape or the thickness of the sample 
(Carvalho & Santos, 2012). 
 
Figure I.16 - Variations in tissue stiffness. The biomechanical properties of a tissue in terms of stiffness (elastic modulus), 
measured in Pascal (Pa), vary markedly between organs and tissues, and are inherently related to tissue function (Cox & 
Erler, 2011). 
 
Single-cell adhesion studies 
Atomic force microscopy-based single-cell force spectroscopy (SCFS) is used to quantify the 
contribution of cell adhesion molecules to the adhesion of cells to specific substrates both at the cell 
and at a single molecule level. In AFM-based SCFS, a single cell is attached to a cantilever, 
commonly facilitated by an adhesive coating (e.g., concanavalin A, poly-L-lysine or CellTak). The 
attached cell is brought into contact with a substrate, which can be a protein-coated surface, another 
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cell or a biomaterial, until a set force is reached. The cell is kept stationary in contact with the surface 
for a set of time to allow the formation of adhesive interactions. During the subsequent retraction of 
the cantilever, the force acting on the cell and the distance between cell and substrate are recorded in a 
force-distance curve. The force values that can be detected with AFM-based SCFS are from ~10 pN 
up to ~100 nN. Thereby, SCFS allows both the overall cell adhesion and the contribution of single 
adhesion receptors to be quantified. During cantilever retraction, the upward acting force on the cell 
increases until the force needed to initiate cell de-adhesion is reached, leading to unbinding events (vd. 
Figure I.17). At the cellular level, single cells can be ingeniously fixed onto the cantilever, becoming 
the probe for the dynamic quantification of cell–substrate interactions (SCFS). Parameters such as 
maximum detachment force and work for the entire cells as well as a number of detachment events of 
single cellular tethers have already been successfully quantified. The maximum force is called the 
adhesion force and it is a measure of how strong cell adhered to the substrate. Unbinding events can be 
characterized either as rupture (jumps) or membrane tether events. The analysis of these unbinding 
events may be used to characterize the strength of single bonds and cell membrane properties 
(Bowman et al., 2012; Yu et al., 2015).  
 
 
Figure I.17 - Schematic overview of AFM-based cell-cell adhesion experiments (a). Force-distance curve showing 
maximum detachment force (Fdetach), work necessary for the cell detachment from the substrate (shaded area) and two types 
of molecular unbinding events: (I) the receptor remains anchored in the cell cortex and unbinds as the force increases 
(designed as jumps) and (II) receptor anchoring is lost and membrane tethers are pulled out of the cell (b). Image from 
(Variola, 2015). 
 
Adhesion is a fundamental aspect of cells, both in health and disease. In the last decade, single cell 
adhesion studies have contributed to the understanding of adhesion proteins and their regulation. 
AFM-based SCFS has been used to quantify adhesion of numerous cell types to a diverse set of 
substrates, include extracellular matrix (ECM) proteins, biomaterials and cell–cell adhesion proteins 
(Yu et al., 2015). 
  
a b 
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II) Objectives 
The two main goals of this thesis were: 
i. To study the influence of fibrinogen molecules on erythrocyte-erythrocyte adhesion of stroke 
patients. 
ii. To evaluate morphological and elasticity changes on erythrocytes from patients with 
Amyotrophic Lateral Sclerosis. 
III) Material and Methods 
1) Blood collection 
Human blood cells were obtained by vein puncture from healthy adult volunteer donors (n=57), used 
as control. The blood collection was performed at Instituto Português do Sangue e da Transplantação 
de Lisboa, Portugal, under an institutional agreement with Instituto Português do Sangue (Lisbon). 
Human blood cells were also obtained by vein puncture from stroke patients and from Amyotrophic 
Lateral Sclerosis patients in a close collaboration with clinicians from Serviço de Medicina I (Prof. 
Carlos Moreira) and Serviço de Neurologia (Prof. Mamede de Carvalho), respectively, from Santa 
Maria Hospital (Centro Hospitalar Lisboa Norte). Healthy donors, stroke and ALS patients samples 
were obtained with their previous written and signed an informed consent, or from their proxy, as 
approved by the joints Ethical Committee of Santa Maria Hospital and of the Faculty of Medicine of 
the University of Lisbon. 
Blood samples from healthy donors (control) and stroke patients were collected into K3EDTA, lithium 
heparin and sodium citrate 3.8% anticoagulant tubes (Vacuette, Greiner Bio-One, Germany) and ALS 
patients were collected into S-Monovette 4.9 mL, Lithium heparin and K3EDTA anticoagulant tubes 
(Sarstedt, Germany). 
K3EDTA, heparin and sodium citrate anticoagulant tubes were used according to the different 
measurements performed to analyse hematologic and haemorheological parameters. K3EDTA is a 
critical factor of coagulation and is particularly useful for haematological examination, being the tri-
potassium salt the most stable. This anticoagulant prevents platelet aggregation, conserves blood cells 
properties and blocks the formation of prothrombin and the beginning of the coagulation process. It is 
used for haemogram and for erythrocyte isolation. 
Heparin is the most widely used anticoagulant for clinical chemistry analysis, because it binds to 
several enzymes responsible for the coagulation cascade. It is present naturally in blood and prevents 
blood cells haemolysis. Heparin tubes were used for analysing haemorheological parameters and for 
fluorescence generalized polarization measurements. 
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Sodium citrate is widely used for coagulation studies. The effect is easily reversible by the addition of 
Ca
2+
. It was used for total fibrinogen and γ’ fibrinogen quantification in plasma (Mafuvadze & 
Erlwanger, 2007; Gonzalez-Covarrubias et al., 2013).  
2) Haemogram 
Haemogram were quantified using whole blood collected into K3EDTA anticoagulant tubes. Analysis 
were done on a Haematological Analyser (PocH-100iV - Hematology Analyzer, Sysmex Europe 
GmbH, Hamburg, Germany). Haemogram allows the counting of each of the human blood cells 
elements and to compare these results with reference ranges for each parameter. About 40 to 45% of 
the blood volume is occupied by erythrocytes. This percentage of volume is termed haematocrit 
(Baskurt & Meiselman, 2003). 
3) Human Blood Cells Isolation 
For human blood cells isolation, the blood was collected into K3EDTA anticoagulant tubes (3mL) and 
cells were isolated as previously described elsewhere (Carvalho et al., 2015). In a refrigerated 
centrifuge (Heraeus Multifuge 1 L-R, Thermo Scientific, UK), blood was centrifuged at 1620 g for 10 
min, at 10ºC, resulting in a three phase solution: an upper phase of plasma, a middle phase of buffy-
coat and a lower phase of erythrocytes. 
The supernatant (plasma and buffy coat) was discarded and the erythrocytes were resuspended in 1 
mL of buffered saline glucose-citrate (BSGC) buffer (1.6 mM KH2PO4, 8.6 mM Na2HPO4, 0.12 M 
NaCl, 13.6 mM sodium citrate, and 11.1 mM glucose) pH 7.3 with CaCl2 (1 mM). On the second 
centrifugation, the supernatant was disposed, without buffer addition, and the erythrocyte mush was 
kept at 4ºC, until further use. 
4) Atomic Force Microscopy  
A NanoWizard II atomic force microscope (JPK Instruments, Berlin, Germany) mounted on the top of 
an Axiovert 200 inverted optical microscope (Carl Zeiss, Jena, Germany) was used for imaging and 
force spectroscopy experiments during this project. 
4.1) AFM Scanning Images of Human Blood Cells  
The AFM head is equipped with a 15 μm z-range linearized piezoelectric scanner and an infrared 
laser. Imaging of the erythrocytes was performed, in air, in tapping mode. Oxidized sharpened silicon 
tips with a tip radius of ~ 6 nm, resonant frequency of about 60 kHz and spring constant of 3 N/m 
were used for the imaging. Imaging parameters were adjusted to minimize the force applied on the 
scanning of the topography of the cells. Scanning speed was optimized to 0.3 Hz and acquisition 
points were 512×512. Imaging data were analysed with the JPK Image Processing software v.5.1.8 
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(JPK Instruments, Berlin, Germany). The diameter, area, height and volume of each imaged cell were 
quantified using the SPIP software v.6.6.0 (Image Metrology, Hørsholm, Denmark). The roughness of 
the erythrocytes was also analysed by Gwyddion software v.2.45 (Czech Metrology Institute, Czech 
Republic) (Carvalho et al., 2010; Bernardes et al., 2016). 
4.2) AFM – based Force Spectroscopy 
For the AFM experiments, the erythrocytes were isolated from the blood plasma. Then the cells were 
suspended into final 0.1% haematocrit with saline glucose-citrate (BSGC) buffer (1.6 mM KH2PO4, 
8.6 mM Na2HPO4, 0.12 M NaCl, 13.6 mM sodium citrate, and 11.1 mM glucose) pH 7.3 with CaCl2 
(1 mM). After this, the solution was placed on a poly-L-lysine-coated glass slide and erythrocytes 
were allowed to adhere firmly for 30 min (Carvalho et al., 2010, 2011, 2015; Guedes et al., 2016). 
AFM indentation for elasticity  
For erythrocyte indentation experiments, non-functionalized OMCL TR-400-type silicon nitride tips 
(Olympus, Japan) were used. The softest triangular cantilevers, with a tip radius of ~15 nm and a 
resonant frequency of 11 kHz, were used. The spring constants of the tips were calibrated by thermal 
fluctuation method having a nominal value of 0.02 N/m. For every contact between the cell and the 
cantilever, the distance between the cantilever and the cell was adjusted to maintain a maximum 
applied force of 300 pN for erythrocytes from ALS patients before retraction. Cell elasticity was 
measured on one point of each erythrocyte (5 force-distance curves per cell). Data collection for each 
force-distance cycle was performed at 1.5 Hz, with a z-displacement range of 4 μm. Force curves were 
made at the centre of the cell. Data acquired on the nanoindentation experiments (force curves) were 
analysed to obtain the cells Young’s modulus (E), using JPK Image Processing software v.5.1.8, by 
the application of the Hertzian model. The probe was modelled as a quadratic pyramid, with a tip 
angle of 35º (half-angle to face) and a Poisson ration of 0.50. Histograms results of the Young’s 
modulus were constructed for each experimental condition studied. The ideal histogram bin size was 
chosen in order to achieve the best fitted Gaussian model peak length. The maximum values of the 
Gaussian peaks represent different statistical measure of the Young’s modulus of the cells. AFM tip 
penetration depth onto erythrocytes was also evaluated. This parameter was analysed by the position 
of the maximal movement of the piezo sensor in the z-axis, which corresponds to the z-axis coordinate 
when the sensor reaches an indentation force of 300 pN for erythrocytes from ALS patients, 
subtracting the z-axis position of the sensor when the tip begins the contact with the surface of the 
erythrocyte (Guedes et al., 2016). 
Protein-cell interactions 
Force spectroscopy measurements were performed on the same equipment using fibrinogen 
functionalized OMCL TR-400-type silicon nitride tips (Olympus). The softest triangular cantilevers, 
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with a tip radius of ~15 nm and a resonant frequency of 11 kHz, were used. For the functionalization, 
AFM silicon nitride tips were cleaned with an intense ultraviolet light source and silanized in a 
vacuum chamber with 3-aminopropyl-triethoxysilane (APTES, 30µl) and N,N-diisopropylethylamine 
(10 µl) for 1 hour in an argon atmosphere. Amine-terminated AFM probes were then placed in 
glutaraldehyde solution 2.5% (v/v) for 20 min and washed 3 times with PBS (phosphate buffered 
saline) pH 7.4. Finally, the tips were placed into fibrinogen solution to attach the fibrinogen 
molecules. Purified human fibrinogen (Sigma Aldrich, USA) was used at a concentration of 1 mg/mL 
with an incubation during 30 min. Fibrinogen-functionalized tips were immediately mounted on the 
atomic force microscope and used for the force spectroscopy measurements (Carvalho et al., 2011, 
2015). Cantilevers with a nominal spring constant of approximately 0.02 N/m were used after their 
calibration using the thermal fluctuation method. The applied force was adjusted to 800 pN, before 
retraction. Data collection for each force-distance cycle was performed at 3 µm/s, leading to an 
average loading rate of ~9 nN/s. For each blood sample, approximately 3000 force vs. distance curves 
were collected, analysed and adjusted by polynomial fit by JPK Image Processing software v.5.1.8 
(JPK Instruments, Berlin, Germany). 
Cell-cell adhesion 
In these AFM studies, a 100 µm long range force-spectroscopy was made possible by the development 
of the CellHesion® module for the BioAFM NanoWizard® (JPK Instruments). They created an 
integrated system for measuring cell-cell and cell-substrate interactions. The objective was mounted 
with a PIFOC® focus tracking system that allows the user to keep the plane of interest in focus at all 
times during the experiments and to enable concurrent movement of the objective with the sample 
holder during force spectroscopy measurements. Tipless cantilevers (Arrow TL1, NanoSensors) with 
1µm of thickness, 0.03 N/m of spring constant and 7 kHz of resonance frequency were used. For this 
study the cantilevers were functionalized for attached the cell to the cantilever, through the cell 
capture, a semi-automatic approach system. The process of the cantilever functionalization for use in 
erythrocytes was based in the work of Wojcikiewicz et al. (2004). This method has good acceptance 
since the streptavidin/biotin system has been well characterized. This complex has high-affinity, and 
the initial layer of biotin-BSA (biotinylated bovine serum albumin) may help to mask any electrical 
charges on the cantilever tip that could lead to nonspecific binding. 
For the functionalization, AFM cantilevers were cleaned with an intense ultraviolet light source for 15 
min. After this, the cantilevers were incubated in a 50 µl drop of biotin-BSA (0.5 mg/mL in 0.1 M 
sodium bicarbonate, pH 8.6; Sigma Aldrich, Germany), overnight at 37°C in a humidified incubator. 
The cantilevers were washed three times in PBS (phosphate buffered saline) pH 7.4 to remove 
unbound protein. After that the cantilevers were incubated to a 50µl drop of streptavidin (0.5 mg/mL 
in 0.01 M PBS, pH 7.4) for 30 min at room temperature. The cantilevers were washed 3 times in PBS, 
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and finally, the cantilevers were incubated in biotin-concanavalin A solution (0.4 mg/mL in PBS, 
Sigma Aldrich, Germany) for 30 minutes at room temperature (vd. Figure III.1).  
 
Figure III.1 - Functionalization of an AFM tip with concanavalin A. Unsharpened Si3N4 AFM cantilevers were 
functionalized with biotinylated bovine serum albumin (biotin-BSA) coupled with avidin bound to biotinylated con A. Figure 
from (Wojcikiewicz et al., 2004). 
Single cells were captured by positioning the con A-functionalized cantilever above the cell centre and 
gently lowering onto the cell for, approximately, 30 seconds. The settings were appropriately 
optimised. The applied force was adjusted to 0.3 nN before retraction. Data collection for each force-
distance cycle was performed at 3 µm/s and with a z-length of 30 µm. A retract delay and an extend 
delay of 5 seconds were applied. We measured the adhesion force in different fibrinogen 
concentrations (from 0 mg/ml to 1.0 mg/ml of fibrinogen) (Sigma Aldrich, USA) for control and 
patients. For each blood sample, approximately, 40 force vs. distance curves were performed for each 
concentration (5 curves × 8 cells attached in a poli-L-lysine glass slides). The incubation with 
fibrinogen was during 15 minutes for each protein concentration tested (0.0, 0.4 and 1.0 mg/mL) 
before the measurements have been performed. Well-defined and measurable adhesion forces curves 
were observed for the interaction between erythrocyte-erythrocyte in the presence and in the absence 
of fibrinogen molecules. Force-distance curves were analysed using JPK Image Processing software 
v.5.1.8 (JPK Instruments, Berlin, Germany). 
5) Haemorheological Parameters 
Rheology is a specialized part of fluid mechanics and is concerned mainly with non-Newtonian and 
viscoelastic substances. A non-Newtonian liquid is one in which the viscosity depends on shear stress. 
The phase blood rheology implies that blood exhibits a variable viscosity depending on how rapidly it 
is forced to flow under shear (Kaibara, 1996). 
A non-Newtonian rheology of blood is considered on the interaction of fibrinogen with erythrocytes. 
At normal haematocrit levels, no other plasma protein in the absence of fibrinogen seems capable of 
producing a yield shear stress in erythrocytes (Kaibara, 1996). 
The blood rheological properties are the basic science and clinical interest. Blood is considered a non-
Newtonian suspension containing cells (e.g., erythrocytes, leukocytes and platelets), lipid components, 
proteins, carbohydrates and electrolytes. Blood flow is characterized by several haemorheological 
parameters and the concentration of cellular elements in blood and their rheological properties are 
important determinants of blood fluidity (Santos et al., 2011). Normal erythrocytes are highly 
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deformable bodies and tend to orient themselves with the flow streamlines, especially if the shear 
forces are high enough to slightly deform these cells. Erythrocyte deformation and orientation are the 
primary cellular factors affecting blood viscosity at high shear rates (Baskurt & Meiselman, 2003). 
Various epidemiological studies indicated a possible relationship between blood rheology and 
coronary heart disease incidence (Sargento et al., 2003; Guedes et al., 2016). To study haemorheology 
it is important to know the characteristics of various types of blood vessels. The arterial system 
consists of aorta, arteries, arterioles, terminal arterioles and capillaries. All vessels have different 
diameter, wall thickness and others characteristics. The venous system consists of veins, vena cava, 
venues and others vessels. As the arterial system, the venous system has different diameter, wall 
thickness and others characteristics. This information can be seen in Figure III.2. 
 
Figure III.2 - Characteristics of various types of blood vessels in humans, mainly in arterial and venous system. (Figure from 
https://s-media-cache-ak0.pinimg.com/236x/07/67/f4/0767f4ccaa40677fbe4975d3aac63ab1.jpg). 
Haemorheological parameters are influenced by all blood cells and blood compounds. On this study, 
the human blood was collected into heparin anticoagulant tubes, and erythrocyte deformability, 
erythrocyte aggregation and whole blood viscosity were determined. 
5.1) Erythrocyte Deformability  
Introduction of the method 
Erythrocytes transports oxygen and they need to traverse the capillaries of the microvascular system 
with internal diameters of 4-5 µm. In normal conditions, the erythrocytes deform sufficiently to across 
these narrow passages. The cellular deformability, defined as the ability of a cell to adopt a new shape 
in response to deforming forces, is essential for microvascular tissue perfusion (Rabai et al., 2014). 
Erythrocyte deformability can be modified by several structural and functional alterations of 
erythrocytes generated by genetic or environmental factors. It is known that the reduction in 
erythrocyte deformability under certain physiological or pathological conditions results into the 
retardation of blood-flow through the microcirculation. The erythrocytes are extremely deformable 
because they can progressively elongate under shear stress. At higher shear stress, the erythrocytes 
respond by elongating itself in capillaries. So they are capable of entering and transiting in blood vases 
with smaller diameters. When the cells deform their surface area remains fixed. The erythrocyte 
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membrane resists to the dilation of its area and only ruptures above 2-3% of its area expansion (Santos 
et al., 2011). 
The unique shape and structure of erythrocytes confer special mechanical properties to them. 
Erythrocytes behave as elastic bodies, and thus the shape change is reversible when the deforming 
forces are removed. Erythrocytes also exhibit viscous behaviour and respond as a viscoelastic body. 
The erythrocytes membrane can exhibit plastic changes under some pathological circumstances and 
can be permanently deformed by excessive shear forces (Baskurt & Meiselman, 2003). The membrane 
elastic and cytoplasmic viscosity properties are determinant factor for erythrocyte deformability. 
Erythrocyte deformability can be quantified by monitoring changes in cell shape after applying fluid 
forces (Baskurt & Meiselman, 2003). In healthy conditions erythrocytes can pass capillaries with 
diameters smaller than their cell size, but if clotting occurs, the blood flow might stop. In the case of 
wound healing, clotting is life-saving, but in a healthy vessel a thrombus might lead to a stroke. 
Pathophysiological processes can result in reversible or irreversible deterioration of erythrocyte 
rheological behaviour (Baskurt & Meiselman, 2003). 
Sample preparation/measurement 
Erythrocyte deformability can be studied by ektacytometry. This technique simulates the fluid flow 
and the vessel wall conditions, in which a laser beam is projected through a dilute erythrocyte 
suspension and the resulting diffraction pattern analysed to determine erythrocyte shape and hence a 
deformation index, also known as an elongation index. The erythrocyte deformability is semi-
quantitatively evaluated (Martins e Silva & Saldanha, 2005). 
For our erythrocyte deformability measurements, the human whole blood was collected into heparin 
anticoagulant tubes and suspended with Dextran 40,000 buffer in isotonic NaCl solution (low 
viscosity), in a final concentration of the suspension 1.5% (v/v). The erythrocyte deformability was 
determined using a shear stress diffractometer (Rheodyne SSD laser diffractometer, Myrenne, 
Roetgen, Germany) at 0.3, 0.6, 1.2, 3.0, 6.0, 12.0, 30.0 and 60.0 Pa shear stress values. These values 
mimic the values of shear stress in blood vases in physiological conditions.  
 
Figure III.3 - Principle of erythrocyte deformability technique. In sample chamber is inserted the erythrocyte solution with 
elevated viscosity between two discs. Upper disk is a rotating optical glass and the fixed disk is a stationary 
polymethacrylate. The diffraction pattern is circular with erythrocytes. A laser beam is allowed to pass through the 
erythrocyte suspension and a diffraction pattern appears. These light intensities are measured along two axes, and the relative 
“Elongation Index” is obtained. The measurement is performed by applying different types of shear stress values in the blood 
sample. Figure from (Martins e Silva & Saldanha, 2005). 
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5.2) Erythrocyte Aggregation 
Introduction of the method 
Erythrocytes aggregation is also one the most important factors affecting the blood flow. The 
increased erythrocyte aggregation is a cardiovascular risk factor, associated with others clinical 
conditions, such hypertension and hypercholesterolemia. Erythrocytes hyperaggregation occurs in 
diabetes, atherosclerosis, arterial hypertension, ischaemic heart disease, stroke and others vascular 
pathologies (De Oliveira et al., 2012). “Pathologic aggregates” are known to occur also in myocardial 
infarction, nephrotic syndrome and after prolonged storage of blood samples (Baskurt & Meiselman, 
2003). 
Erythrocyte aggregation occurs when biconcave discoid cells “stick” face-to-face to form the so-called 
“rouleaux” at sufficiently-low shear forces (Baskurt & Meiselman, 2003, 2007). Erythrocyte 
aggregation is also dependent on the local shear forces, as the aggregates are reversible and easily 
broken into smaller aggregates (or individual cells) under increasing shear forces. An important 
consequence of this shear-dependent nature of erythrocyte aggregation is the non-newtonian behaviour 
of blood. Blood viscosity increases with increase number of erythrocyte aggregates, holding more 
cells into three-dimensional rouleaux under low-shear conditions (Baskurt & Meiselman, 2003, 2007). 
Erythrocyte aggregation is a major determinant of the in vitro rheological properties of blood (Neu et 
al., 2008). It is known that an increase of fibrinogen concentration and of erythrocyte aggregation are 
significant risk factors during various cardiovascular and cerebrovascular diseases (Lominadze & 
Dean, 2002). Erythrocyte aggregation can be influence by biochemical, haemorheological and 
haemodynamic factors. At low shear rates observed at venous system an increase in erythrocyte 
aggregation induce an increase in blood viscosity and consequently impaired blood velocity 
(Saldanha, 2002). The mechanism of erythrocyte aggregation is that it results from an increase in 
plasma adhesion proteins such as fibrinogen (Lominadze & Dean, 2002). Fibrinogen and others 
plasma proteins promote erythrocyte aggregation, with aggregation dependent on the magnitude of 
shearing forces acting on the cells (Baskurt & Meiselman, 2003). 
There are two models proposed for erythrocyte aggregation: (i) the “Bridging model” that bridging 
forces due to the adsorption of macromolecules onto adjacent cell surfaces exceed disaggregating 
forces; and (ii) the “Depletion model” that result of a lower localized protein or polymer concentration 
near the cell surface compared to the suspending medium. Disaggregation forces are electrostatic 
repulsion, membrane strain, and mechanical shearing (Neu et al., 2008). 
Sample preparation/measurement  
Blood cells suspension were prepared with different fibrinogen (fraction I, type I, human plasma, 
Sigma, ref. F-3879) concentration (0, 20, 40, 60, 80 mg/dL) into NaCl 0.9% that were added to 500 µL 
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of human blood. Blood was collected into heparin anticoagulant tube. The suspensions were incubated 
for 30 minutes, in room temperature. The erythrocyte aggregation was measured in a Myrenne 
aggregometer (model MA-1, Myrenne GmbH, Roetgen, Germany). The system measures the infrared 
light transmission through an erythrocyte suspension between a transparent plate and a cone, at stasis 
during 5 s and 10 s after dispersion of the blood samples, or rotation at shear stress of 600 s
-1
 (Santos 
et al., 2011). 
5.3) Whole Blood Viscosity 
Introduction of the method 
Blood and plasma viscosity are one of the major factors affecting blood flow and normal circulation. 
Whole blood viscosity is chiefly affected by plasma viscosity, erythrocyte deformability, haematocrit, 
and other physiological factors. Increase in the blood viscosity was associated with the development of 
multiple disorders via damaging the vascular endothelium. It also has a correlation between blood 
viscosity and cerebrovascular disorders (Alkuraishy et al., 2014). Plasma viscosity depends of the 
concentration of plasma proteins, and it has Newtonian fluid properties. Plasma viscosity was 
considered as a marker of acute disease due to elevation of plasma proteins mainly fibrinogen 
(Alkuraishy et al., 2014). Blood viscosity is higher in patients with cerebrovascular disorders due to 
higher haematocrit, and this is correlated with infarct size and increase of the risk of mortality 
(Alkuraishy et al., 2014). Increase in the blood viscosity induces endothelial damage, inflammation, 
vascular wall hypertrophy, platelet aggregation and deterioration in the blood vessels shear stress. All 
these factors increase the risk of a stroke and cardiac ischemia events. Blood viscosity is usually 
higher at the morning. This circadian rhythm is due to higher fibrinogen level at morning which 
explained the higher rate of stroke during that time (Alkuraishy et al., 2014). Gender differences in 
blood viscosity is related to the erythrocytes rigidity and aging. The degree of disturbance of flow 
streamlines and consequently the viscosity of blood is thus strongly dependent on the haematocrit. 
There are major dissimilarities among males and young females at reproductive period in whole blood 
viscosity. Different studies previously showed that high haematocrit and blood viscosity were 
significantly correlated with male cerebrovascular disorders (Alkuraishy et al., 2014). Because of the 
female menstruations there are significant gender differences in all viscosity parameters, as for the 
decrease of haematocrit leading to lower blood viscosity in female. Approximately 0.8% of total red 
blood cells reformed per day, and 80% of female erythrocytes were younger (Alkuraishy et al., 2014). 
Thus, the viscosity of the blood depends on the viscosity of the plasma in combination with the 
haematocrit. Higher haematocrit implies higher viscosity (Westerhof et al., 2005). For normal blood at 
37°C, blood viscosity at high shear rate (100~200 s
-1
) is measured as 4 ~ 5 cP (Kim et al., 2012).  
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Sample preparation/measurement 
Whole blood viscosity was evaluated in a Brookfield digital viscometer (Brookfield, USA). For that it 
was used native whole blood collected into heparin anticoagulant tube, submitted to low (22.5 s
-1
) and 
high (225 s
-1
) shear rates, both at a native and after correction of the haematocrit of 45%, and at 37ºC. 
Viscosity of a liquid depends on its temperature, so the viscosity of blood is usually measured at 
constant temperature by a rotational viscometer. Several units have been used for viscosity, with the 
most common being milliPascal.sec (mPa.s) which is numerically equal to centipoise (cP). The blood 
in the human circulatory system is affected by wide variations in shear rate and the viscosity 
measurements can be variable in 6.0 to 8.0 mPa.s at low shear rate and 4.4 to 5.2 mPa.s at high shear 
rate (Martins e Silva & Saldanha, 2005; Santos et al., 2011; Guedes et al., 2016). 
 
6) Fibrinogen Quantification 
6.1) Total Plasma Fibrinogen Quantification 
Increased levels of plasma fibrinogen result in changes in blood rheological properties, and these 
alterations exacerbate the complications in peripheral blood circulation during cardiovascular 
pathologies. Thus, it is important to quantify the fibrinogen levels in human plasma. For fibrinogen 
quantification, the blood was collected into sodium citrate anticoagulant tube. In a centrifuge (Sorvall 
TC6), blood was centrifuged at 3000 rpm for 10 min. The plasma was collected for the fibrinogen 
quantification measurement which was performed in Dade Behring BFT II Coagulation Analyzer 
(Behring, Germany). 
The coagulation analyser is a semi-automated, dual-channel coagulometer, and its permit the 
fibrinogen quantification in mg/dL Used a temperature-controlled incubation block for reagents 
(Multifibren*U, Siemens) and samples, at 37ºC (vd. Figure III.4). The Multifibren*U method is a 
modification of the Clauss method, a functional assay based upon the time for fibrin clot formation, 
where the citrated plasma is brought to coagulation by a large excess of thrombin. Here the 
coagulation time depends largely on the fibrinogen content of the specimen (Siemens Healthcare 
Diagnostics Products, 2008). 
 
Figure III.4 - Process of total plasma fibrinogen quantification using the Multifibren*U method. 
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6.2) γ’ Fibrinogen Quantification 
For the quantification of γ’ fibrinogen, it was done an assay that is intended to be used as part of a risk 
for cardiovascular disease assessment in adults. In a centrifuge (Sorvall TC6), blood collected into 
sodium citrate anticoagulant tube is centrifuged at 3000 rpm for 10 min. The γ’ fibrinogen assay uses 
human venous plasma samples. It is a semi-automated quantitative ELISA method that consists in a 
two-site sandwich immunoassay by Gamma Coeur Test Kit (Gamma Therapeutics, Inc., Portland, 
Oregon). γ’ fibrinogen in the sample binds to a specific monoclonal antibody for this protein which 
was coated on the 96-microwells plate (vd. Figure III.5). Every sample was done in duplicated. After 
incubation, unbounds non- γ’ fibrinogen, such as γAγA fibrinogen, and others plasma components (vd. 
Figure III.5B) were removed by sequential washing. Horse radish peroxidase (HRP)-labeled 
polyclonal secondary antibody was added, which binds to the captured γ’ fibrinogen, forming a 
“capture antibody/analyte/detection antibody” sandwich (vd. Figure III.5D). After this, excess 
detection antibody was removed by several sequential washings and a substrate for the HRP-labeled 
detector was added to generate a coloured product (vd. Figure III.5E). After the secondary antibody, a 
solution to stop the reaction was added to each well and the absorbance of the yellow coloured end 
product was read on a spectrophotometer at 450 nm. The average of each set of duplicates was 
calculated for each samples (healthy donors, stroke and ALS patients) and the results from the 
standards were confirmed (Mannila et al., 2007; Lovely et al., 2010; Farrell, 2014). Eight solutions of 
γ’ fibrinogen with increased fibrinogen concentrations were used as calibrators of a standard 
calibration curve (Farrell, 2014).  
 
Figure III.5 - Process of the γ’ fibrinogen quantification by ELISA method. 
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7) Zeta-Potential 
7.1) Introduction of the method 
Most liquids contain ions, and a charged particle is suspended in a solution of an opposite charge will 
be attracted to the surface of the suspended particle (Malvern Instruments, 2004). The liquid layer 
surrounding the particle exists as two parts, an inner region, where the ions are strongly bound, that is 
commonly called the stern layer. The stern layer has composed by positive ions that are called 
counter-ions. The attraction from the negative charged membrane surface causes some of the positive 
ions to form a firmly attached layer. The second layer is the diffuse layer, where ions diffuse more 
freely, less firmly associated and is composed by negative and positive ions. This causes a dynamic 
equilibrium because the positive ions are still attracted by negative colloid but they are repelled by the 
stern layer (vd. Figure III.6) (Freire et al., 2011; Malvern Instruments, 2011). 
A potential exists between the particle surface and the dispersing liquid which varies according to the 
distance from the particle surface is the zeta-potential (ζ-potential) (Malvern Instruments, 2004). Zeta-
potential is a physical property which is exhibited by any particle in suspension (Malvern Instruments, 
2011) and this is calculated based on the electrophoretic mobility of the particles in solution, on an 
electric field, to the electrode of opposite charge (Domingues et al., 2008; Freire et al., 2011). 
The ζ-potential is used as a combination of two measurement techniques: electrophoresis and Laser 
Doppler velocimetry. The electrophoretic mobility of the scattering particles in a sample can be 
calculated essentially by Laser Doppler velocimetry (Malvern Instruments, 2004). Laser Doppler 
velocimetry is a technique that relates the frequency measured by intensity fluctuation of the scattered 
light. The sensitivity of the Doppler Effect to the low mobility of larger particles is very low, causing 
difficulties in calculating the electrophoretic mobility (Domingues et al., 2008; Freire et al., 2011). 
The zetasizer Nano Series calculates the ζ-potential by determining the electrophoretic mobility and 
then applying the Henry equation. The development of a net charge at the particle surface affects the 
distribution of ions in the surrounding interfacial region. The magnitude of the ζ-potential gives an 
indication of the potential stability of the colloidal system.  
The Henry equation is defined by: 
 
𝜁 =  
3𝜂𝑢
2𝜀𝑓(𝑘𝑎)
 (2) 
Where 𝜂 is the viscosity of the solvent, 𝑢 is the electrophoretic mobility, 𝜀 is the dielectric constant 
and 𝑓(𝑘𝑎) is the Henry’s function. The value of this function is considered to be 1.5 when the 
particles are suspended in aqueous solutions with high ionic strength (Smoluchowski’s approximation, 
that fits well to physiological conditions), and 1 when non-aqueous media are used (Huckel 
approximation). Using this simple approach the surface charge potential of molecules in solution and 
the change in this parameter, as a result of interactions with biologically relevant ligands, can be easily 
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monitored. Thus, allowing the determination of the role of charges in biological interactions. The ζ-
potential of a particle is proportional to its surface charge (Domingues et al., 2008). 
 
Figure III.6 - Composition of erythrocyte and zeta-potential of their surface membrane. The erythrocyte has a negatively 
charged surface membrane and this causes some of the positive ions to form a firmly attached layer. The ions have strongly 
bound to particle (Stern layer). The diffuse layer, where ions diffuse more freely is composed by negative and positive ions. 
A potential exists between the particle surface and the dispersing liquid which varies according to the distance from the 
particle surface, is the Zeta-Potential (ζ-potential) (Malvern Instruments, 2004). 
7.2) Samples preparation and measurement 
Human blood was collected into K3EDTA anticoagulant tube and erythrocytes were isolated according 
the already described procedure. BSGC with CaCl2 buffer at pH 7.3 were filtered using a syringe filter 
with 0.45 µm pore size (Whatman, Florham Park, NJ) to remove any large scattering particle, which 
would bias the light scattering measurements. The erythrocytes suspension was set to 0.035% of 
haematocrit in BSGC with CaCl2 buffer pH 7.3, in the absence or in the presence of different soluble 
human variants fibrinogen concentrations (0.0-2.0 mg/mL). With a 1 mL syringe, the sample was 
injected into the folded capillary cell (DTS 1060) (Malvern, UK) (vd. Figure III.7).  
 
Figure III.7 - Process for inserting the sample into the folded capillary cell (a). Scheme of the Zeta-Potential: with the 
erythrocytes suspension (I), and erythrocytes suspension with fibrinogen molecules (II) (b). Images adapted from (Malvern 
Instruments, 2004).  
On this project, it was used a software to control the measurement of the sample. SOP measurements 
can be pre-defined the settings for all the measurement. Zeta-potential analysis were performed as 
described by Carvalho et al.(2011). Measurements were conducted on a ζ-potential equipment 
Malvern Zetasizer Nano ZS (Malvern, UK), equipped with a He-Ne laser (λ=632.8 nm). The ζ-
potential of the samples were determined, at 25ºC, from the mean of 15 measurements, with 60 runs 
each, with an applied potential of 30V, in absence and presence of different soluble human fibrinogen 
concentrations (0.4 at 2.0 mg/mL), using a specific cuvette (Carvalho et al., 2011). Before the 
measurements, the samples were allowed to pre-incubate for 10 minutes.  
 
Negative charge of erythrocyte membrane 
Stern Layer 
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8) Fluorescence Generalized Polarization 
8.1) Introduction of the method 
The rheological properties, and other cellular functions, such as permeability and mobility, are 
regulated by membrane fluidity. An approach of fluidity can be made by using fluorescence 
polarization with fluorescent probes distributed in the lipid areas of membranes (Donner & Stoltz, 
1985). On this study was used laurdan (2-dimethylamino-6-lauroylnaphthalene), that is a polarity 
sensitive probe. Laurdan was designed and synthesized by Gregorio Weber, to study the phenomenon 
of dipolar relaxation. It is a naphthalene derivative, which is used as a fluorescent dye when applied to 
fluorescence microscopy (Sanchez et al., 2012). The fluorescent naphthalene moiety of these probes 
has a dipole moment due to a partial charge separation between the 2-dimethylamino and the 6-
carbonyl residues. This dipole moment increases upon excitation and may cause reorientation of the 
solvent dipoles. The bilayer fluidity-dependent fluorescence spectral shift of laurdan can have dipolar 
relaxation phenomena. Upon excitation, the dipole moment of laurdan increases noticeably and water 
molecules in the proximity of the probe reorient around this new dipole. When the membrane is in a 
fluid phase, the reorientation rate is faster than the emission process and, consequently, a red-shift is 
observed in the emission spectrum of laurdan. When the bilayer packing increases part of the water 
molecules is excluded from the bilayer and the dipolar relaxation of the remaining water molecules is 
slower, leading to a fluorescent spectrum which is significantly less shifted to the red (Domenech et 
al., 2010). The emission spectrum of laurdan within a single phospholipid bilayer is centered at 490 
nm when the lipids are in a disordered phase and is shifted to the blue (around 440 nm) when the lipids 
are in a more packed phase (Sanchez et al., 2012). Changes in lipid fluidity can sometimes be related 
with either pathological processes or membrane alterations caused by cell interactions with exogenous 
molecules. It is therefore important that the indications obtained regarding lipid fluidity should be 
accurately correlated with membrane structure or functions. However, biological membranes represent 
very heterogeneous media and the use of probes which label different compartments of cell 
membranes is required to get a better knowledge of membrane fluidity. Polarity changes are detected 
by shifts in the laurdan emission spectrum, and the Generalized Polarization function (GP) was 
defined as a way of measuring wavelength displacements. Changes in GP values when lipid bilayers 
are either in fluid or gel phase extended the use of the technique to the field of membrane dynamics 
and protein interaction (Sanchez et al., 2012). The concentration and molecular dynamics of the water 
molecules is a function of the phospholipid phase state, where water reorientation along the probe 
excited-state dipole occurs only in the liquid-crystalline phase. The Generalized Polarization (GP) 
function is defined as: 
 
𝐺𝑃 =  
𝐼440 − 𝐼490
𝐼440 + 𝐼490
 (3) 
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where I440 and I490 are the emission intensities at 440 and 490 nm respectively. It is used to investigate 
membrane qualities of the phospholipid bilayers of cell membranes. The hydrophobic tail of the lauric 
fatty acid allows solubilisation of the probe within phospholipid bilayers, locating the fluorescent 
moiety toward the aqueous environment. When laurdan get the phospholipid bilayers, it can be seen in 
Figure III.8 some water molecules penetrating the lipid bilayer (Yu et al., 1996). 
 
Figure III.8 - Scheme of laurdan anchored into phospholipid bilayers in presence of some water molecules and localized in 
ordered lipid phase and disordered lipid phase. Adapted from (Parasassi et al., 1998; Harris et al., 2002).  
In phospholipid bilayers laurdan is tightly anchored in the hydrophobic core by the cooperative van 
der Waals interactions between the lauric acid tail and the lipid hydrocarbon chains, with its 
fluorescent moiety residing at the level of the phospholipid glycerol backbone (Parasassi et al., 1998). 
Cuvette measurements of laurdan GP are done in a conventional fluorometer using excitation light at 
340-360 nm and by simply registering the two mentioned emission intensities (Sanchez et al., 2007). 
8.2) Samples Preparation and Measurement 
Human venous blood samples were collected into heparin anticoagulant tube from healthy donors and 
ALS patients. Whole blood samples were centrifuged for 5 min at 3000 rpm in Sorvall TC6 centrifuge 
(Du Pont, Bad Naughem, Germany). Erythrocytes were isolated according the procedures mentioned 
before. The erythrocytes suspension was set to 0.037% of haematocrit in phosphate buffer 155mM, pH 
7.4. The erythrocyte suspension was incubated for 30 min, at room temperature, in absence (baseline) 
and in the presence of fluorescent probe laurdan, with the total final concentration of 3.59 μM. 
Laurdan was dissolved in DMSO (di-methyl sulphoxide). The Fluorescence Generalized was 
measured on a Varian Cary Eclipse fluorescence spectrophotometer (Mulgrave, Australia). The 
measurements were done with λexc=350 nm, and acquiring the full spectra between 400 nm and 600 
nm. Typical spectral bandwidths were 5 nm for excitation and 10 nm for emission. Excitation and 
emission spectra were corrected for wavelength-dependent instrumental factors. After the 
measurements, it was necessary to normalize the spectra for the maximum, and to calculate the 
Generalized Polarization of the samples. 
Laurdan molecule 
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9) Statistical Analysis 
For each parameter, both groups of the patients (stroke and ALS patients) were compared with the 
control group of healthy donors. The statistical intergroup comparison was performed by applying the 
unpaired Student's t test. Data are shown as mean value ± standard error of the mean (S.E.M.). 
Statistical significance was valued for values of p<0.05 with 95% of confidence interval. Statistical 
analyses were performed using GraphPad Prism 5.03. 
  
-35- 
IV) Results and Discussion 
1) Results with Stroke patients 
At the time of the writing of this thesis it was impossible for us to obtain the clinical data of each 
stroke patient included on the project. 
The erythrocyte deformability was determined by exposing the cell to different shear stress values that 
vary between 0.3 and 60.0 Pa. These values represent the shear stress inside blood vessels of different 
diameters in physiological process. The results are presented in Figure IV.1. It can be seen that, at low 
shear stress, which represent the larger diameter vessels, the erythrocytes from stroke patients are 
more deformable than erythrocytes from control (* p=0.0234 at 0.3 Pa, ** p=0.0039 at 0.6 Pa, * 
p=0.0430 at 1.2 Pa). In smaller diameter vessels, at high shear stress the erythrocytes from stroke 
patients has lower deformability than erythrocytes from control (* p=0.0424 at 12.0 Pa). 
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Figure IV.1 - Erythrocyte deformability measured at different shear stress values for stroke patients (n=6) and control group 
(n=57). Values are presented as mean ±SEM. At low shear stress, that represent the higher diameter vessels, the erythrocytes 
from stroke patients’ are more deformable than erythrocytes from control (* p=0.0234 at 0.3 Pa, ** p=0.0039 at 0.6 Pa, * 
p=0.0430 at 1.2 Pa). With the increased of the shear stress, lower diameter vessels promote an increase of erythrocyte 
deformability, but in smaller diameter vessels, at high shear stress the erythrocytes from stroke patients are less deformable 
than erythrocytes from control (* p=0.0424 at 12.0 Pa).  
The results from erythrocyte aggregation are detailed, in Figure IV.2. The erythrocyte aggregation was 
measured by the infrared light transmission through a whole blood suspension, at stasis during 5 
seconds (vd. Figure IV.2a) and 10 seconds (vd. Figure IV.2b), with the addition of different fibrinogen 
concentrations (0.0 to 80.0 mg/dL). It could be observed that without addition of fibrinogen, at 5 and 
10 seconds, the erythrocytes from stroke patients had a lower tendency to aggregate than the control. 
Erythrocyte aggregation increased with increasing of fibrinogen concentration in control samples. In 
stroke patients the dependence of the addition of fibrinogen concentration is not evident. The 
erythrocyte aggregation in stroke patients measured at 5 seconds (vd. Figure IV.2a) and 10 seconds 
(vd. Figure IV.2b) in presence of fibrinogen 20.0 mg/dL, is higher than the control. Although, these 
difference were not statistically significant. In blood samples from stroke patients it appears that there 
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is a saturation of fibrinogen molecules on plasma which leads to a plateau of erythrocyte aggregation 
index values. 
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Figure IV.2 - Erythrocyte aggregation measured in function of the addition of fibrinogen on blood from stroke patients (n=6) 
and control group (n=57) with addition of the different concentrations of fibrinogen (0.0 to 80.0 mg/dL). The erythrocyte 
aggregation was measured during 5 seconds (a) and 10 seconds (b). Values are presented as mean±SEM.  
 
Figure IV.3 shows the results of the whole blood viscosity, measured in blood from stroke patients and 
control at low (22.5 s
-1
) and high (225 s
-1
) shear rates, both at a native (vd. Figure IV3a,b,c) and 
corrected samples with haematocrit of 45% (vd. Figure IV.3d, e, f), at 37ºC. The applied shear rate and 
the diameter of the vessels are inversely proportional mimicking the physiological process. An 
increase of the shear rate, promotes a decrease of the viscosity of the blood being this related with 
smaller diameter vessels (vd. Figure IV.3c, f). On the other hand, at low shear rate, there was an 
increase of the viscosity, and this occurs in higher diameter vessels (vd. Figure IV.3c, f). At all shear 
rates, both the groups have not statistically significant differences on their whole blood viscosity 
values. But, it is possible to see that stroke patients have a tendency for higher values of viscosity than 
the control. At low shear rate the control values of viscosity was of 7.25±0.17 mPa.s vs. 7.68±0.11 
mPa.s from stroke patients (vd. Figure IV.3a). For whole blood viscosity with haematocrit at 45% the 
control group has 7.22±0.08 mPa.s vs. 7.64±0.45 mPa.s from stroke patients (vd. Figure IV.3d). At 
high shear rate (vd. Figure IV.3b, e), it is observed that the control for native blood viscosity showed a 
tendency for lower viscosity than the stroke patients (4.40±0.08 mPa.s vs. 4.70±0.14 mPa.s). For 
haematocrit at 45% at high shear rate the same tendency was observed (4.51±0.05 mPa.s vs. 4.66±0.11 
mPa.s). All the comparisons of results from control and stroke patients were not statistically 
significant. 
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Figure IV.3 - Variations on whole blood viscosity between stroke patients and control. The whole blood viscosity was 
measured in blood from stroke patients (n=6) and control (n=57) at low (22.5 s-1) and high (225 s-1) shear rates, both at a 
native (a, b, c) and corrected samples with haematocrit of 45% (d, e, f), at 37ºC. Values are presented as box with median 
and whiskers with maximum and minimum values (a,b,d,e) and mean±SEM (c,f). 
Total fibrinogen levels were quantified on stroke patients and control group (vd. Figure IV.4a). 
Increasing plasma fibrinogen levels can result in changes in blood rheological properties, and these 
alterations exacerbate the complications in peripheral blood circulation during cardiovascular 
pathologies. The normal range of the total fibrinogen concentration on the plasma is 180 to 350 mg/dL 
and elevated fibrinogen levels have been associated with a risk factor for cardiovascular disease. Thus, 
it can be seen that stroke patients have high fibrinogen concentration in plasma than the control group 
(290.7±19.31 mg/dL vs. 220.3±7.29 mg/dL, *** p=0.0007, respectively). Despite these differences 
between groups, both values are within the normal range of the total fibrinogen concentration levels in 
plasma. 
γ’ fibrinogen plasma levels were also quantified (vd. Figure IV.4b). Values that fall above the cut-off 
value (>30 mg/dL, represented by grey dashed line), may be indicative of increased risk of 
cardiovascular disease. Thus, it can be observed that stroke patients has higher concentration of γ’ 
fibrinogen in plasma than control (54.61±7.29 mg/dL vs. 32.48±1.60 mg/dL, *** p<0.0001, 
respectively). The ratio between γ’ fibrinogen and the total fibrinogen for each sample were also 
calculate (vd. Figure IV.4c). We could observed that stroke patients have more percentage of γ’ 
fibrinogen in their plasma than the control (18.95±2.37 % vs. 14.83±0.70 %, * p=0.0384, 
respectively). As it is expected that the percentage of γ’ fibrinogen in healthy conditions is 
approximately 15%, we could observed that stroke patients have increased risk of cardiovascular 
disease. 
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Figure IV.4 - Fibrinogen levels on plasma of stroke patients (n=6) and control (n=34). Total plasma fibrinogen levels (*** 
p=0.0007) (a). γ’ fibrinogen plasma quantification (*** p<0.0001) (b). Ratio between γ’ fibrinogen and total fibrinogen 
concentration present on each stroke patients and control. γ’ fibrinogen levels on the plasma from stroke patients is higher 
than in plasma from control (* p=0.0384) (c). Values are presented as box of whiskers that represent the median and 
maximum and minimum values. 
In parallel with the other methods, erythrocyte elasticity measurements were also performed on both 
studied groups (vd. Figure IV.5). All the force spectroscopy data were analysed in order to determine 
the Young’s modulus (vd. Figure IV.5a) and the penetration depth (vd. Figure IV.5b) for each force-
distance curve. For the Young’s modulus measurements, it can be seen that the erythrocytes from 
stroke patients are stiffer than the erythrocytes from control (3512±1440 Pa vs. 128.3±19.28 Pa, * 
p=0.0267, respectively). The Young’s modulus of the erythrocytes from stroke patients is higher than 
control. This result is associated with the lower penetration depth of the erythrocytes from stroke 
patients. The penetration depth (vd. Figure IV.5b) was analysed by the position of the maximal 
movement of the piezo sensor in the z-axis. This corresponds to the z-axis coordinate when the sensor 
reaches an indentation force of 800 pN, subtracting the z-axis position of the sensor when the tip 
begins the contact with the surface of the erythrocyte. Lower penetration of the erythrocytes from 
stroke patients indicates that these erythrocytes are capable to deform less than those from control 
(526.4±1.44 nm vs. 811.3±7.305 nm *** p<0.0001, respectively). 
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Figure IV.5 - Erythrocyte stiffness measured by Atomic Force Microscopy. The stiffness or Young’s modulus, of the 
erythrocytes from stroke patients (n=6) and control (n=7) were analysed. The values are represented as box of whiskers that 
represent the median and maximum and minimum values of the maximum Gaussian peaks (* p=0.0267) (a). Values of 
penetration depth with AFM tip onto erythrocytes. The penetration depth was analysed with an indentation force of 800 pN. 
This parameter can measure the capacity of the erythrocytes to deform. The values are represented as box of whiskers that 
represent the median and maximum and minimum values (*** p<0.0001) (b). 
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In Figure IV.6, the interaction between fibrinogen and erythrocyte membrane receptor was measured 
by atomic force microscopy-based force spectroscopy. In Figure IV.6a was assessed the fibrinogen-
erythrocyte binding force, in picoNewton from stroke patients and control. It can be observed that the 
force necessary to break the interaction between fibrinogen and erythrocytes from stroke patients is 
higher than the control. These values were not statistically significant but it can be observed that they 
have different intervals of distribution. The results showed that the force necessary to break the bond 
between fibrinogen and erythrocytes increases from 40.42±3.00 pN in control to 67.51±20.26 pN in 
stroke patients (p=0.0543). We also calculate the percentage of binding frequency (%) and the results 
are shown in Figure IV.6b. The probability of the frequency of the binding between fibrinogen and 
erythrocytes was higher in control than in erythrocytes from stroke patients (27.6±4.2% vs. 9.23±2.76 
%, * p=0.0172, respectively). Thus, in stroke patients, the force necessary to break this interaction is 
higher but the frequency of the binding was lower. So, in stroke, the erythrocytes can interact more 
with fibrinogen but less frequently. 
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Figure IV.6 - AFM-based force spectroscopy data for the fibrinogen-erythrocyte interactions. Fibrinogen-erythrocyte 
binding force (pN) in erythrocyte from stroke patients and control (p=0.0543) (a). Binding frequency (%) was measured by 
AFM in erythrocytes from stroke patients and control (* p=0.0172) (b). The values are represented as box of whiskers that 
represent the median and maximum and minimum values.  
Erythrocyte-erythrocyte adhesion studies using an AFM were also performed (vd. Figure IV.7). Figure 
IV.7a represents the work (fJ) necessary to detach two erythrocytes from each other. Without the 
addition of fibrinogen, when the erythrocytes interact, the work necessary to detach two erythrocytes 
was higher in stroke patients than the control (2.86±0.29 fJ vs. 0.48±0.03 fJ, *** p<0.0001, 
respectively). So we could conclude that erythrocyte-erythrocyte adhesion, in stroke patients, was 
stronger than for the control. The increase on fibrinogen concentration promotes erythrocyte-
erythrocyte adhesion in erythrocytes from control. At 1.0 mg/mL of fibrinogen, the adhesion between 
erythrocytes from stroke patients was less strong than the control (2.38±0.22 fJ vs. 2.88±0.34 fJ, 
respectively). The detachment force (pN) was also measured in function of the addition of fibrinogen 
and it is shown in Figure IV.7b. The detachment force is the maxima force necessary to detach two 
erythrocytes. Without fibrinogen addition, the detachment force between erythrocytes from stroke 
patients was higher than for the control (103.0±0.03 pN vs. 70.20±0.23 pN, *** p<0.0001, 
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respectively). Identically to the values of the work (vd. Figure IV.7a), in detachment force when the 
fibrinogen concentration increases, it promotes erythrocyte-erythrocyte adhesion and this effect is 
more pronounced on the control. At 1.0 mg/mL of fibrinogen, the force necessary to break the 
interaction between the erythrocytes is higher in stroke patients than on control (152.4±0.24 pN vs. 
137.0±0.89 pN, *** p<0.0001, respectively). Thus, with the increase of the fibrinogen concentration, 
the interaction between two erythrocytes was stronger in stroke patients than for the control. 
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Figure IV.7 - Erythrocyte-erythrocyte adhesion study by AFM-based force spectroscopy measured in function of the 
different fibrinogen concentration. The work (fJ) necessary to break the adhesion between two erythrocytes from stroke 
patients and control, in absence and presence of fibrinogen molecules (*** p<0.0001) (a). Values of detachment force (pN), 
in function of different fibrinogen concentrations, in erythrocytes from stroke patients and control (*** p<0.0001) (b). Values 
are presented as mean ±SEM. 
From the force-distance curve, it is possible to extract two other parameters that are important to 
understand the adhesion of the erythrocytes in stroke patients and control: the jumps and membrane 
tethers. In Figure IV.8 it is possible to observe the results from these parameters. Jumps and 
membrane tethers were measured on erythrocyte-erythrocyte adhesion curves in absence and presence 
of the fibrinogen concentrations, from stroke patients and controls (vd. Figure IV.8a,b). The jumps 
events gave results about the force (pN) that occurs when the membrane of erythrocytes break the 
interactions between them. When the detachment occurs, the cells are separated and the bonds 
between ligands and receptors break. Without fibrinogen addition, the erythrocytes from stroke 
patients need to have stronger forces to break the interaction between them than for the control 
(85.42±24.75 pN vs. 47.78±0.31 pN, respectively). In presence of 1.0 mg/mL of fibrinogen the value 
of force of the jumps was lower than for the control but they were not statistically different 
(81.09±17.51 pN vs. 147.76±1.49 pN, respectively). In Figure IV.8b it is represented the values of the 
membrane tether forces (pN), which is other type of unbinding between membranes. Without 
fibrinogen, the erythrocytes from stroke patients need higher force to detach membrane tethers than 
control (62.12±19.68 pN vs. 34.98±0.10 pN, respectively). With addition of 1.0mg/mL of the 
fibrinogen, tethers in erythrocyte membrane from stroke patients were less strong than in erythrocyte 
membrane from control (83.57± 19.30 pN vs. 155.57± 1.21 pN, respectively). 
a b 
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Figure IV.8 - Values of force of jumps (a) and membrane tethers (b) events formed after the binding between two 
erythrocytes from stroke patients and controls. Values are presented as mean ±SEM.  
 
On this study, we used different parameters, essentiality AFM and haemorheological parameters, to 
better understand the interaction between fibrinogen and erythrocytes in stroke patients.  
From the erythrocyte deformability technique we could conclude that erythrocytes from stroke patients 
are more deformable at low shear stress values, but less deformable at high shear stress values. With 
the increased of the shear stress, lower diameter vessels promote an increase of erythrocyte 
deformability. In smaller diameter vessels, at higher shear stress, the erythrocytes from stroke patients 
have lower deformability than erythrocytes from control. The same effect was stated by Guedes et al. 
(2016) but using erythrocytes from chronic heart failure patients, also a cardiovascular disease 
(Guedes et al., 2016). Erythrocyte aggregation has pathogenic implications in thrombus formation. 
From the results we could conclude that erythrocytes from stroke patients have more tendency to 
aggregate. Also stroke patients have higher whole blood viscosity.  
The quantification of the higher fibrinogen levels in plasma from stroke patients was also performed. 
This parameter has been associated with an elevated cardiovascular risk factor. Stroke patients also 
have higher γ’ fibrinogen levels in plasma. They have an increase of the fibrinogen (total and γ’ 
variant) quantification in plasma that is associated with high risk of cardiovascular events and could 
lead to a stroke event.  
With AFM results, we could conclude that fibrinogen-erythrocyte interactions were modified in stroke 
patients.  
Like in chronic heart failure disease (Guedes et al., 2016), the fibrinogen-erythrocyte binding forces in 
stroke patients could be a potential biomarker for the risk assessment of the disease. The fibrinogen 
and erythrocytes interact more but with less binding frequency. The stiffness and penetration depth of 
the erythrocytes was also assessed and was concluded that the erythrocytes from stroke patients are 
stiffer and have lower penetration depth. The elasticity results confirm the results achieved with 
erythrocyte deformability technique. 
Even without addition of the fibrinogen, from the erythrocyte-erythrocyte adhesion studies, we could 
conclude that stroke patients have erythrocytes with different membrane components that promote 
higher adhesion between them. Differences on erythrocyte membrane cytoskeleton complex are thus 
a b 
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expectable, promoting an increase of the changed in adhesion of the erythrocytes. In the presence of 
fibrinogen, the adhesion between two erythrocytes was stronger. These results indicate that fibrinogen 
could promote the interaction between the erythrocytes from stroke patients. 
With all these results we could conclude that erythrocytes from stroke patients are less deformable, 
having more tendency to aggregate. Also these patients have the blood more viscous, higher levels of 
total fibrinogen and γ’ fibrinogen in plasma and the interaction between fibrinogen and its erythrocytes 
are stronger. All these factors are significant risk factors for a bad prognostic of the stroke disease. 
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2) Results with Amyotrophic Lateral Sclerosis patients 
The clinical profiles of the Amyotrophic Lateral Sclerosis patients studied on this thesis are 
summarized in Table IV.1. The group was settled for their demographic, clinical and laboratorial data.  
Table IV.1 - The demographical and clinical parameters of ALS patients. 
Clinical profile of ALS patients 
 ALS patients 
Demographics 
No. of patients 
Age (mean ±s.d.) 
Male/Female (%) 
10 
65.6 ±11.4 
70/30 
Duration since disease onset (No. of patients) 
<1 year 
1-2 years 
>2 years 
3 
3 
4 
Onset form (No. of patients) 
Spinal 
Bulbar 
Respiratory 
7 
2 
1 
ALS-FRS (No. of patients) 
0-10 
11-20 
21-30 
31-40 
1 
0 
3 
6 
Respiratory Insufficiency (No. of patients) 
8 
9 
10 
12 
1 
2 
1 
6 
Forced Vital Capacity (No. of patients) 
≥80% 
<80% 
Not available 
3 
4 
3 
Abbreviations: ALS patients, Amyotrophic Lateral Sclerosis 
patients; ALS-FRS, Amyotrophic Lateral Sclerosis Functional 
Rating Scale; s.d., standard deviation 
 
As for stroke patients, we also assessed the erythrocyte deformability of ALS patients and compared 
with control group. The results are presented in Figure IV.9. It could be observed that at low shear 
stress, that represent larger-diameter vessels, the erythrocytes from ALS patients are more deformable 
than erythrocytes from control (*** p=0.0004 at 0.3 Pa, *** p<0.0001 at 0.6–3.0 Pa, ** p=0.0041 at 
6.0 Pa). High values of shear stress, in smaller diameter vessels, promote an increase of erythrocyte 
deformability. In smaller diameter vessels, the erythrocytes from ALS patients have a tendency to be 
more deformable than erythrocytes from control, but the results were not statistically significant. 
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Figure IV.9 - Erythrocyte deformability measured at different shear stress values. Variations on erythrocyte deformability by 
elongation index between ALS patients (n=7) and control group (n=57). Values are presented as mean ±SEM. Statistical 
significance: *** p=0.0004 at 0.3 Pa, *** p<0.0001 at 0.6–3.0 Pa, ** p=0.0041 at 6.0 Pa. 
 
Other haemorheological parameter that was assessed was the erythrocyte aggregation. In Figure IV.10, 
the erythrocyte aggregation was measured by the infrared light transmission through a whole blood 
suspension, at stasis during 5 seconds (vd. Figure IV.10a) and 10 seconds (vd. Figure IV.10b), with the 
addition of different fibrinogen concentrations (0.0, 40.0 and 80.0 mg/dL). It could be observed that 
without addition of fibrinogen, at 5 and 10 seconds, the erythrocytes from ALS patients have a lower 
tendency to aggregate than the control. With the addition of fibrinogen there was an increase of the 
erythrocyte aggregation in both groups but the differences between ALS patients and control values 
were not statistically significant. 
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Figure IV.10 - Erythrocyte aggregation measured in function of the fibrinogen addition to blood samples from ALS patients 
(n=7) and control (n=57), during 5 seconds (a) and 10 seconds (b), Values are represented as mean±SEM. This parameter 
was not statistically significant between the studied groups. 
 
Figure IV.11 shows the results for the whole blood viscosity measured in samples from ALS patients 
and control at low (22.5 s
-1
) and high (225 s
-1
) shear rates, both at a native (vd. Figure IV.11a, b, c) and 
corrected samples with haematocrit of 45% (vd. Figure IV.11d, e, f), at 37ºC. The applied shear rate 
and the diameter of the vessels are inversely proportional mimicking the physiological process. An 
increase of the shear rate, promotes a decrease of the viscosity of the blood being this related with 
smaller-diameter vessels (vd. Figure IV.11c, f). On the other hand, at low shear rate, there was an 
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increase of the viscosity, and this occurs in higher diameter vessels (vd. Figure IV.11c, f). At native 
blood viscosity, and low shear rate, the ALS patients are more viscous than the control (p<0.0001). At 
low shear rate the control has 7.27±0.18 mPa.s vs. 9.51±0.90 mPa.s from ALS patients, and for blood 
viscosity with haematocrit at 45% the control group has 7.22±0.09 mPa.s vs. 7.49±0.28 from ALS 
patients, (vd. Figure IV.11a, d, respectively). At high shear rate (vd. Figure IV.11b, e), it is observed 
that the control for native blood viscosity showed a tendency for lower blood viscosity than the ALS 
patients (4.40±0.08 mPa.s vs. 4.80±0.34 mPa.s, respectively). For haematocrit at 45% at high shear 
rate the tendency is the same for the control and ALS patients (4.51±0.05 mPa.s vs. 4.60±0.19 mPa.s, 
respectively). Both differences were not statistically significant. 
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Figure IV.11 - Changes on whole blood viscosity of ALS patients and control. The whole blood viscosity was measured and 
submitted between ALS patients (n=7) and control (n=57) at low (22.5 s-1) and high (225s-1) shear rates, both at a native (a, 
b, c) and corrected samples with haematocrit of 45% (d, e, f), at 37ºC. Values are presented as box with the median value and 
whiskers with maximum and minimum values (a,b,d,e) and mean±SEM (c,f). At low shear rate (a), the statistical value is *** 
p<0.0001. The native blood viscosity at high shear rate did not statistically differ neither the values of blood viscosity with 
haematocrit at 45% at low and high shear rate (d, e, f). 
 
 
The γ’ fibrinogen plasma levels of the ALS patients and control were also quantified (vd. Figure 
IV.12). The increase of γ’ fibrinogen plasma levels can results in changes in blood rheological 
properties. This variant has been associated as a cardiovascular risk factor. Values that fall above the 
cut-off value (>30 mg/dL, represented by grey dashed line), may be indicative of increased risk of 
cardiovascular disease. Thus, it could be seen that the ALS patients has higher concentration of γ’ 
fibrinogen in plasma than control (52.55±4.00 mg/dL vs. 33.78±1.60 mg/dL, *** p<0.0001, 
respectively). 
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Figure IV.12 - γ’ fibrinogen plasma quantification in ALS patients (n=10) and control (n=47). Values are presented as box 
with median value and whiskers with maximum and minimum values. Cut-off value (>30 mg/dL, represented by grey dashed 
line), may be indicative of increased risk of cardiovascular disease (*** p<0.0001). 
 
The membrane fluidity of the erythrocytes from control and ALS patients was determined by 
generalized polarization used laurdan fluorescent probe (vd. Figure IV.13). It is known that, in 
membrane fluidity studies, based on fluorescent generalized polarization of laurdan, the GP values can 
range from 1 to -1. Negative values are obtained as a consequence of the solvent relaxation 
phenomenon associated with laurdan-water interactions when membrane lipids are disordered. GP 
values of erythrocyte from ALS patients were more negative than the ones for control (* p=0.0236). 
These results indicate that the erythrocyte membrane from ALS patients could be disordered and less 
compacted than control. Erythrocytes with less compaction of the membrane, when interacts with 
laurdan can incorporate water molecules into its membrane leading to low GP values. These results 
could be associated with the possibility of the membrane of the erythrocytes from ALS patients having 
some alterations in their lipid bilayer composition. The erythrocytes from ALS patients are more fluid 
than the control. 
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Figure IV.13 - Erythrocyte membrane fluidity measured by fluorescent generalized polarization with laurdan, a fluorescence 
probe. It was measured erythrocytes from ALS patients (n=7) and control (n=5). Values are presented as box with median 
value and whiskers with maximum and minimum values (* p=0.0236).  
In parallel with the others applied techniques, erythrocyte elasticity measurements in the ALS patients 
and control group, were also performed (vd. Figure IV.14). All the force spectroscopy data were 
analysed in order to determine the Young’s modulus (vd. Figure IV.14a) and the penetration depth (vd. 
Figure IV.14b) for each force-distance curve. Erythrocytes from ALS patients are stiffer than the 
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erythrocytes from control (5032±4792 Pa vs. 128.3±19.28 Pa, respectively). The penetration depth (vd. 
Figure IV.14b) was analysed by the position of the maximal movement of the piezo sensor in the z-
axis, which corresponds to the z-axis coordinate when the sensor reaches an indentation force of 300 
pN, subtracting the z-axis position of the sensor when the tip begins the contact with the surface of the 
erythrocyte. The erythrocytes from ALS patients have more penetration depth than the erythrocytes 
from control, indicating that the erythrocytes from ALS patients are more capable to deform than the 
control (829.6±5.36 nm vs. 811.3±7.305 nm, * p=0.0437, respectively). 
The elastic properties of the erythrocytes have never been investigated in ALS disease. Changes in 
viscoelastic properties of the erythrocytes in these patients would have impact on peripheral hypoxia, 
which is related to tolerance to exercise and functional outcome. 
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Figure IV.14 - AFM stiffness studies. Values of Young’s modulus from ALS patients (n=10) and control (n=7). The results 
are presented as maximum Gaussian peaks (mean±SEM) (a). Penetration depth of the AFM tip on erythrocytes. The 
penetration depth was analysed in erythrocytes from ALS patients (n=10) and control (n=7) by the position of the maximal 
movement with an indentation force of 300 pN (* p=0.0437) (b). Values are presented as box with median value and 
whiskers with maximum and minimum values  
Performing AFM scanning images of the erythrocytes from ALS patients it was possible to assess 
their morphology and compare it with the control (vd. Figure IV.15). Examples of AFM height and 
error images obtained for the erythrocytes from ALS patients and controls could be visualized in Table 
IV.2 of this thesis. Results of the erythrocytes diameter could be analysed on Figure IV.15a. It can be 
observed that the erythrocytes from ALS patients have higher diameter than erythrocytes from control 
(8.513±0.018 μm vs. 8.296±0.016 μm, *** p<0.0001, respectively). The area of the erythrocytes from 
ALS patients was also higher than the control (57.23±0.23 μm2 vs. 54.19±0.16 μm2, *** p<0.0001, 
respectively) (vd. Figure IV.15b). Erythrocytes from ALS patients were also taller than erythrocytes 
from control (0.593±0.002 μm vs. 0.572±0.003 μm, *** p<0.0001, respectively) (vd. Figure IV.15c). 
Erythrocyte from ALS patients have slightly less volume than erythrocytes from control (21.10±0.25 
μm3 vs. 21.81±0.22 μm3,* p=0.0315, respectively) (vd. Figure IV.15d). Erythrocytes from ALS 
patients had a larger distribution of the morphological values than the control. 
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Figure IV.15 - Results of AFM scanning imaging of erythrocytes from ALS patients (n=10) and control (n=7). 
Morphological characterization of erythrocytes, throught the analysis of different parameters: diameter (a), area (b), height 
(c) and volume (d).Values are presented as box with median value and whiskers with maximum and minimum values. 
Statistical values represents are: (a, b, c) *** p<0.0001, (d) * p=0.0315. 
Another parameter that could be assessed through the analysis of the AFM images of the erythrocytes 
was the surface roughness (vd. Figure IV.16). Erythrocyte membrane roughness average (Ra) was 
assessed (vd. Figure IV.16a) which is defined by the mean of the absolute values of the height of the 
surface profile. From the results it could be observed that the average roughness (Ra) of the 
erythrocytes from ALS patients is lower than the control. Thus, the surface of the erythrocyte from 
ALS patients was less rough than the surface of the erythrocytes from control (1.31±0.07 nm vs. 
1.72±0.15 nm, * p=0.0176, respectively). Values of the Root Mean Square Roughness (Rq) were also 
analysed (vd. Figure IV.16b). This parameter is more specific for the measurement of the surface 
roughness because it can distinct the peaks and valleys on the surface profile. Thus, the surface of the 
erythrocytes from ALS patients have less membrane profile perturbances which means that is less 
rough than the surface of the erythrocytes from the control (1.73±0.08 nm vs. 2.13±0.19 nm, * 
p=0.0479, respectively). 
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Figure IV.16 – Erythrocyte membrane roughness of control (n=7) and ALS patients (n=10). The average roughness (Ra) (a) 
and Root Mean Square Roughness (Rq) (b) were measured. Values are presented as box with median value and whiskers 
with maximum and minimum values. Statistic values represented are: (a) * p=0.0176, (b) * p=0.0479.  
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Zeta-Potential of the erythrocytes was also assessed (vd. Figure IV.17) to analyse the variation of the 
electrostatic forces in erythrocytes from ALS patients and control, in the absence or in the presence of 
different fibrinogen concentrations. Without the addition of fibrinogen it could be observed that the 
erythrocytes from ALS patients have a more positive surface charge than the control, (-12.18±0.06 
mV vs. -12.80±0.09 mV, *** p<0.0001, respectively) (vd. Figure IV.17a). When fibrinogen (0.4 
mg/mL) was added, the charge of the erythrocytes from ALS patients altered and stays more positive 
than control (-10.85±0.08 mV vs. -11.23±0.11 mV, ** p=0.0087, respectively). Increasing the addition 
of fibrinogen the charge of the erythrocytes became even more positive in both samples, but without 
statistically significant differences between them (vd. Figure IV.17b). At higher concentration of 
fibrinogen, the membranes of the erythrocytes could be saturated of fibrinogen molecules leading only 
to a slightly variation of the charge of the cellular membrane. The Δζ curves (vd. Figure IV.17c) have 
a tendency to achieve a plateau at high concentration of fibrinogen (~ 2 mg/mL). From these curves it 
could hypothesized that the erythrocyte membranes of ALS patients became saturated with less 
number of fibrinogen molecules added. This fact could be explained by the less negatively charged 
membranes of the erythrocyte from ALS patients when no fibrinogen molecules were added. 
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Figure IV.17 - Zeta-potential of the erythrocytes from ALS patients (n=10) and control (n=7), without (a) and with addition 
of different concentrations of fibrinogen (b). Values are presented as box with median value and whiskers with maximum 
and minimum values (a). The values are presented as mean ±SEM (b). Variation of zeta-potential of the erythrocytes (c). 
Statistic values represented are: (a) *** p<0.0001; (b) *** p<0.0001 and ** p=0.0087. 
Other zeta-potential studies were performed with erythrocytes from healthy donors and in the presence 
of different concentrations of fibrinogen variants (γAγA and γAγ’ fibrinogen). In Figure IV.18a it 
could be observed that, without the presence of fibrinogen, the erythrocyte membrane has a value of 
zeta-potential of -12.80±1.10 mV, which is lower than in the presence of fibrinogen concentration. At 
0.4 mg/mL of γAγA and γAγ’ fibrinogen, there was no significant variation of zeta-potential between 
both variants (-11.92±0.60 mV vs. -11.96±0.93 mV, respectively). The negatively charge erythrocyte 
membrane has high affinity for fibrinogen molecules. Thus its membrane charge became more 
positive due to the binding of fibrinogen on the erythrocyte membrane. At 0.7 mg/mL of fibrinogen 
concentration, the membrane charge of erythrocyte in the presence of the γAγ’ fibrinogen is more 
positive than in the presence of γAγA fibrinogen (-11.88±0.65 mV vs. -12.22±0.78 mV, respectively). 
It could be hypothesized that γAγ’ fibrinogen has higher affinity for erythrocyte membrane than γAγA 
fibrinogen. Figure IV.18b shows the values of the variation of Zeta-Potential (Δζ) for each sample 
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which was calculated by subtracting the zeta-potential value of the erythrocytes in the presence of 
fibrinogen by the initial value (corresponding to the value of Δζ at zero fibrinogen concentration). 
From the results it could be seen that γAγA fibrinogen at 0.4 mg/mL has higher affinity for erythrocyte 
membrane than γAγ’ fibrinogen. Also, at 0.7mg/mL of γAγA fibrinogen the value of Δζ did not vary 
significantly and the curve achieve a plateau. This could mean that, at γAγA fibrinogen concentration 
higher than 0.4 mg/mL, the erythrocyte membrane is saturated with fibrinogen molecules attached to 
it. At all γAγ’ fibrinogen concentrations tested on this study, the erythrocytes membrane did not reach 
the saturation (vd. Figure IV.18b). 
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Figure IV.18 - Zeta-potential of erythrocytes from healthy donors (n=4) in the absence and in presence of different 
concentrations (0.4 and 0.7 mg/ml) of the fibrinogen (γAγA and γAγ’ variants) (a). Variation of the zeta-potential (Δζ) for 
the same erythrocytes and conditions (b). Values are represented as mean ± SEM. 
It is known that a deviation of the zeta-potential to more positive values can be associated with the 
removal of sialic acid, because it is the principal source of the negative charge on the erythrocytes 
membrane (Carvalho et al., 2011; Fernandes et al., 2011). Therefore in control conditions, the 
presence of γAγ’ fibrinogen promotes less reduction of sialic acids on erythrocyte membrane and has 
less interaction with it. This study is important for comprehension the changes of the charge of the 
erythrocyte membrane, and their relation with affinity, interaction and adhesion to γAγ’ fibrinogen, 
that is related with high cardiovascular risk events. This part of the study was only performed with 
erythrocytes from healthy donors due to the low amount of fibrinogen solution available in the 
laboratory for conducting these experiments (especially γAγ’ fibrinogen). Knowing that ALS patients 
has higher fibrinogen γAγ’ concentration in the plasma than healthy donors (vd. Figure IV.12), in the 
future, it will be extremely important to conduct the same experiments but with erythrocytes isolated 
from ALS patients. 
2.1) Special clinical cases 
Knowing all the results from ALS patients it is possible to highlight three clinical cases. 
ALS patient I, represented by the purple colour point in the graphics, is a 43-years-old woman with 
diagnostic of amyotrophic lateral sclerosis with a spinal onset form, a score of 27 in ALS-FRS scale, 
and a total survival time of 1.3 years before the date of blood collection for this study. This patient had 
a deep venous thrombosis event on the day before the collection of the blood. ALS patient II, 
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represented by the blue point in the graphics, is a 72-years-old man with diagnostic of ALS spinal 
onset form, a score of 10 in ALS-FRS scale, and a total survival time of 21.7 years before the date of 
blood collection. ALS patient III, represented by the grey point in the graphics, is a 73-years-old man 
with diagnostic of ALS and a total survive time of 2.5 years before the date of blood collection. This 
patient has the respiratory onset form and a score of 29 in ALS-FRS scale. The graphics below (vd. 
Figure IV.19 to Figure IV.25) are identical to the ones already shown above, but highlighting the 
specific colours of each special clinical case. 
On Figure IV.19, it could be observed that ALS patient II have the lowest viscosity of all ALS patients 
studied, at low and high shear rate and in native whole blood or with haematocrit correction at 45%. 
This haemorheological parameter has not been measured for ALS patient I. The ALS patient III has a 
value of viscosity close to the mean for the whole blood viscosity. 
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Figure IV.19 - Variations on whole blood viscosity of ALS patients (n=7) and control (n=57) at low (22.5 s-1) and high 
(225s-1) shear rates, both at a native (a, b) and corrected samples with haematocrit of 45% (d, e), at 37ºC. ALS patient II 
(blue point) and ALS patient III (grey point) are highlighted.  
All ALS patients have γ’ fibrinogen concentration values above the cut-off value (>30mg/dL) (vd. 
Figure IV.20). ALS patient I has one of the lowest value of the γ’ fibrinogen in plasma, but ALS 
patients II and III presented high levels of γ’ fibrinogen in plasma. These patients are much older than 
the ALS patient I. Thus, this result can indicate that the increase of the γ’ fibrinogen quantification in 
plasma could be associated with increasing the age of patient, and also with increasing risk of 
cardiovascular disease. This result is contradictory with the fact that ALS patient I is the one that had a 
deep venous thrombosis event. It is not reported any cardiovascular disease event in patients ALS II 
and III clinical history. 
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Figure IV.20 - γ’ Fibrinogen plasma quantification in ALS patients (n=10) and control (n=47) by semi-automated 
quantitative ELISA method. Values that fall above the cut-off value (>30 mg/dL, represented by grey dashed line), may be 
indicative of increased risk of cardiovascular disease (*** p<0.0001). ALS I patient (purple point), ALS patient II (blue 
point) and ALS patient III (grey point) are highlighted. 
Erythrocyte membrane fluidity was only possible to be determined on ALS patients II and III. ALS 
patient II has the more negative value of GP than all the ALS patients. By the contrary, the erythrocyte 
fluidity of ALS patient III was the less negative. This could mean that the erythrocyte membranes of 
ALS patient III could be more ordered and high compacted. One of the main clinical differences 
between patients II and III is that patient II has a spinal onset form and patient III has a respiratory 
onset form. Whether this could explain or not these differences in erythrocyte membrane fluidity is a 
subject that will need to be clarified. These results indicate that the erythrocyte membrane from ALS 
patients can be disordered and less compacted than control. 
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Figure IV.21 - Erythrocyte membrane fluidity study based with fluorescent generalized polarization of laurdan, a 
fluorescence probe. ALS patient II (blue point) and ALS patient III (grey point) are highlighted  
 
From the erythrocyte membrane zeta-potential data it was possible to observe that ALS patient III has 
more positively charge of the membrane of the erythrocyte than the others patients. ALS patient I and 
II had values approximately the same as the mean of the ALS patients group. The fact that the 
erythrocyte membrane from ALS patient III is more positively charge and less fluid could be 
associated with their respiratory failure.  
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Figure IV.22 - Zeta-potential of erythrocytes from ALS patients (n=10) and control (n=7), without fibrinogen addition (*** 
p<0.0001). ALS I patient (purple point), ALS patient II (blue point) and ALS patient III (grey point) are highlighted. 
The Young’s modulus of the erythrocytes and the penetration depth of the same ALS patients were 
analysed. ALS patient I, represented at purple point, has the highest value of the Young’s modulus and 
the lowest value of the erythrocyte penetration depth (vd. Figure IV.23). ALS patient II (blue point) 
had also a high value of the Young’s modulus. ALS patient III, the grey point, had a medium value of 
the Young’s modulus but a low value of the erythrocyte penetration depth. ALS patient I had stiffer 
erythrocytes and less deformable which could be associated with a higher risk of having a 
cardiovascular event. In fact a deep venous thrombosis event was reported on the clinical history of 
this patient on the day before the collection of the blood. 
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Figure IV.23 – Erythrocyte stiffness by Atomic Force Microscopy in ALS patients vs control. Young’s modulus (a) and 
penetration depth of the AFM tip on erythrocytes (b). ALS I patient (purple point), ALS patient II (blue point) and ALS 
patient III (grey point) are highlighted. 
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In Table IV.2, it could be observed some examples of AFM height and error images obtained for the 
control and for ALS patients (I, II and III). 
Table IV. 2 - Morphological properties of erythrocytes measured by atomic force microscopy from control and ALS patients 
(ALS patient I, II and III). Column A: AFM height image with relative colour scale (80 μm × 80μm). Column B: the 
respective AFM error signal image. Column C: examples of the morphological analysis of the erythrocytes done using a 
specific software (SPIP™ software, Image Metrology, Inc.). 
  
Analysing Table IV.2, it could be observed that exists differences between the erythrocytes from 
control and ALS patients.  
In Figure IV.24, it could be observed that ALS patient I had values for the erythrocytes morphology 
close to the average value of the ALS patient group. On ALS patient II, the erythrocytes have higher 
diameter and area, but have lower volume than the average value of all the ALS patients. The 
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erythrocytes from ALS patient III were taller and had more volume than erythrocytes from others ALS 
patients. 
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Figure IV.24 - Morphological characterization of erythrocytes by the analysis of AFM scanning images from ALS patients 
and control. The erythrocyte diameter (a), area (b), height (c) and volume (d) were measured. ALS I patient (purple point), 
ALS patient II (blue point) and ALS patient III (grey point) are highlighted.  
ALS patient I and II have higher erythrocyte surface roughness (Root Mean Square Roughness) than 
the erythrocytes from all ALS patients (vd. Figure IV.25). 
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Figure IV.25 - Erythrocyte membrane roughness of control and ALS patients. The average roughness (Ra) (a) and Root 
Mean Square Roughness (Rq) (b) were measured. ALS I patient (purple point), ALS patient II (blue point) and ALS patient 
III (grey point) are highlighted. 
 
It has been associated with Amyotrophic Lateral Sclerosis an elevated risk for venous 
thromboembolism. On this study it was investigated the importance of different parameters to 
understand which morphological changes and interactions of the erythrocytes exists on ALS patients.  
From the AFM results, it was possible to assess the erythrocyte morphological and elastic properties 
and conclude that erythrocytes from ALS patients are higher and taller, and have less membrane 
roughness than the controls. They also have more penetration depth and a tendency to be stiffer than 
the erythrocytes from control. These results indicate that, in ALS disease, it occurs changes on 
erythrocyte membrane. D’ Angelo et al. (2013) shown that the proteins and peptides are susceptible to 
a variety of chemical modifications that can affect their structure and biological functions (D’Angelo 
a b 
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et al., 2013). The composition of the membrane of the erythrocyte could be changed, and among these 
modifications, the isomerization of aspartic acid and deamination of asparagine occur in proteins and 
peptides during cell aging. Cytoplasmatic enzymes can also decline during erythrocyte aging 
(Carvalho et al., 2011). The enhanced deamidation/isomeration of the erythrocyte membrane proteins 
may affect the phenotype of the pathophysiology of the disease (D’Angelo et al., 2013). A variety of 
induced stress conditions, including oxidation, has been shown to significantly increase the 
isoaspartate residue content in erythrocytes. It has been demonstrated that specific erythrocyte 
membrane proteins, among which, in particular, cytoskeletal components are substrates for the 
methyltransferase (D’Angelo et al., 2013). The young’s modulus and penetration depth are higher. 
This could be due to changes in the cytoskeletal components, such as the bands 2.1 (ankyrin) and 4.1, 
which are the proteins that provide some rigidity to the membrane (D’Angelo et al., 2013). Other 
changes on erythrocyte membrane components and organization are associated with the age of the 
erythrocytes, which include changes on carbohydrates (exposure of b-galactosyl residues that are 
recognized by lectin-like receptors), proteins (e.g., modification of band 3 protein) and decrease on the 
activities of several enzymes (including enzymes of the glycolytic and pentose shunt pathways, 
involved in cell thiol metabolism and protection against oxidative damage) (Carvalho et al., 2011). 
Other important component of the membrane in erythrocytes is the glycophorin A, a major 
sialoglycoprotein of human erythrocyte membrane. It is the major contact or receptor membrane 
polypeptide that also spans the lipid bilayer. This network is tethered to the cell membrane mediated 
by ankyrin that couples spectrin to band 3 and the other mediated by protein 4.1 that couples the 
junctional complex to glycophorin C/D (Kim et al., 2015). Knowing the results of membrane fluidity, 
lower generalized polarization of the erythrocytes from ALS patients could be associated with the lipid 
composition of the membrane and lipid packing. The band 3 is an anion channel, which is responsible 
for water and anion transportation. It is a major transmembrane glycoprotein in erythrocyte, and it 
transport anions by proteolytic cleavage or aggregation. Negative values of the membrane fluidity are 
associated with water penetration in the membrane when the probe gets in phospholipid bilayer. Thus, 
these changes on erythrocyte membrane in ALS allow the internalization of water molecules and 
promoted lower packing and membrane fluidity. Zeta-potential results showed that the erythrocytes 
from ALS patients have less electronegativity on its surface. These results can be explained by the 
possible differences on the number of sialic acids that constitute the erythrocyte membrane. The sialic 
acid content of cellular membranes may account for up to half of the negative charge of the cell 
surface (Nanetti et al., 2008). The negatively charged of the sialic acids stabilize glycoprotein 
conformation in cell surface receptors to increase cell rigidity. The rigidity of the erythrocytes from 
ALS patients was also altered. This can be due to the glycophorin A that could also be modified. In 
our previous studies (Carvalho et al., 2011), we observed that the removal of the number of sialic 
acids decreases the percentage of fibrinogen-erythrocyte receptor binding events, without significantly 
affecting the (un)binding forces of each interaction. An alteration in the lipid composition 
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(phospholipids, glycolipids) and loss of asymmetry between the inner and outer leaflets of the lipid 
bilayer is also associated with erythrocytes senescence. The interaction between phosphatidylserine 
and the cytoskeleton component spectrin triggers the accumulation of large amounts of 
phosphatidylserine and phosphatidylethanol amine on the outer leaflet erythrocyte membrane 
(Carvalho et al., 2011). Thus, a possible reduction of the sialic acid content in membrane of the 
erythrocytes from ALS patients could promote a more positive membrane charge, as shown by our 
results.  
In parallel with these results, it was possible to conclude that erythrocytes from ALS patients are more 
deformable with increasing the shear stress values. These results confirm the AFM stiffness results, 
because the erythrocytes from ALS patients are stiffer and have more penetration depth than control. 
About the erythrocyte aggregation (with the addition of the fibrinogen) the erythrocytes from ALS 
patients have more tendency to increase its aggregation. So a decrease of membrane sialic acids 
content may contribute to the erythrocytes transient aggregation in circulation. The blood from ALS 
patients are more viscous and have more γ’ fibrinogen content in plasma. This parameter has been 
associated with an elevated cardiovascular risk factor, and venous thrombotic risk. When the fibrin 
clots are formed in the presence of the γ’ fibrinogen, they are more resistant to fibrinolysis. 
Furthermore, the γ’ chain contains a binding site for thrombin, and clots made from γ’ fibrinogen have 
been reported to have altered clot architecture (Domingues et al., 2016). So, ALS patients have higher 
risk of venous thrombosis, due to the elevated γ’ fibrinogen concentration in their plasma. An increase 
in erythrocyte membrane aggregation has also been considered as a cardiovascular risk factor. 
Therefore changes on these erythrocyte parameters could promote thrombolytic events, in ALS 
patients. 
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V) General Conclusions and Future Work 
The purposes of this project were (i) to study the influence of fibrinogen on erythrocytes adhesion in 
stroke patients; and (ii) to evaluate morphological and elasticity changes on erythrocytes from ALS 
patients. Erythrocytes from stroke patients were evaluated by their haemorheological properties and by 
atomic force microscopy. Atomic force microscopy was used to measure fibrinogen-erythrocyte 
interaction, erythrocytes stiffness and erythrocyte-erythrocyte adhesion, in the presence of different 
fibrinogen concentrations. Atomic force microscopy-based force spectroscopy measurements, at the 
single-molecule level, showed that the fibrinogen-erythrocyte binding forces are increased in stroke 
patients, despite its lower binding frequency. Erythrocyte-erythrocyte adhesion showed that, with 
increasing fibrinogen concentrations, the work and the maximum force necessary to detach two 
erythrocytes are increased. Thus, erythrocytes from stroke patients have more tendency to aggregate. 
Additionally, these patients have an increase of the plasma γ’ fibrinogen concentrations and have more 
viscous blood. Stiffness studies revealed that erythrocytes from stroke patients are less deformable 
than the control. All these alterations of the erythrocytes from stroke patients are significant risk 
factors for a bad prognostic of the stroke disease. Also it has to be taken in consideration that the 
binding between fibrinogen and erythrocyte could be a new cardiovascular risk factor for stroke 
disease. 
Erythrocytes from ALS patients were also evaluated by their haemorheological behaviour and by 
atomic force microscopy. AFM was used to measure stiffness and evaluate morphological changes of 
the erythrocyte from ALS patients. The results revealed that erythrocytes from ALS patients are more 
capable to deform than the control. Changes on their erythrocyte morphology were also found. 
Erythrocytes from ALS patients have a less rough membrane than the control and the cells have higher 
area and height. Moreover, ALS patients have an increase of the plasma γ’ fibrinogen concentrations 
and the blood is more fluid. Furthermore, membrane fluidity and zeta-potential studies in erythrocytes 
from ALS patients revealed that the erythrocyte membrane has changed. These changes in erythrocyte 
membrane could promote interactions between fibrinogen and erythrocytes and between two 
erythrocytes which as to be considered a risk factor for thromboembolism venous event. 
Therefore, using AFM and others biophysical techniques, it was possible to evaluate the physico-
chemical-electrical, mechanical and morphological properties of the erythrocytes from patients with 
stroke or ALS disease. The results could help to understand the role of fibrinogen on erythrocyte 
aggregation, and others parameters (eg. membrane lipid composition), which may be relevant for 
potential future drug interventions to reduce aggregation and enhance microcirculatory flow 
conditions in patients with venous thromboembolism risk. 
These results were achieved with a smaller group of stroke (n=6) and ALS (n=10) patients. In the 
future, it is important to enlarge the number of the samples to have a more pronounced effects of both 
diseases on the studied parameters. Also, our findings could contribute to dissect the complex 
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interplay between respiratory function, progression rate, lipid profile and survival in ALS. This could 
help to find a molecular biomarker of early respiratory dysfunction in ALS patients that could 
comprise prognostic value. 
Finally the role of membrane changes of erythrocytes in tissue hypoxia is a relevant novel issue that 
deserves appropriate investigation. Only increasing the number of the patients and confirming our 
findings it will be possible to translate them for clinical application. 
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